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Summary: Calcium (Ca2+) release from intracellular stores controls numerous cellular processes, in-
cluding cardiac and skeletal muscle contraction, synaptic transmission and metabolism. The ryanodine 
receptors (RyRs: RyR1, RyR2, RyR3) and inositol 1,4,5-trisphosphate receptors (IP3Rs: IP3R1, 
IP3R2, IP3R3) are the major Ca2+ release channels (CRCs) on the endo/sarcoplasmic reticulum 
(ER/SR). RyRs and IP3Rs comprise macromolecular signaling complexes that include modulatory 
proteins which regulate channel activity in response to extracellular signals resulting in intracellular 
Ca2+ release. Here we focus on the roles of CRCs in heart, skeletal muscle, brain, metabolism, and aging. 
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INTRODUCTION 
 Calcium (Ca2+) is an essential signaling molecule in all 
cells. Indeed, Ca2+ is involved in numerous fundamental 
functions, including cell life and death [1-4]. Between these 
two events, Ca2+ finely regulates countless events as gene 
transcription, secretion, muscle contraction, and generation 
of fuels in various metabolic pathways, to name but a few [5-
8]. Cytosolic Ca2+ signals are produced by rapidly increasing 
the concentration of free Ca2+ ions [9] by opening channels 
permeable to Ca2+ either in the surface cell membrane or in 
the membranes of intracellular organelles containing high 
Ca2+ concentrations, namely the endoplasmic and sarcoplas-
mic reticula (ER, SR). Amplification of external stimuli by 
triggering the release of intracellular Ca2+ stores is a common 
signaling mechanism in the cell. The ER/SR represents a 
heterogeneous compartment constituted by interconnected 
network of tubules [10, 11]. Besides constituting the major 
Ca2+ reservoir within the cell, being thereby crucial in the 
fine regulation of intracellular Ca2+ concentration, the ER/SR 
is involved in a plethora of functional processes [12], includ-
ing protein synthesis and protein transport, stress signaling, 
lipid synthesis, carbohydrate metabolism and detoxification 
reactions [5, 13-15]. 
 The ER/SR of most cell types presents two types of intra-
cellular Ca2+ release channels (CRC): the ryanodine receptors 
(RyRs) and the inositol 1,4,5-trisphosphate receptors (IP3Rs)  
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[16]. There is ~40% homology between the RyR and lP3R in 
the putative transmembrane regions, a sequence similarity 
sufficient to indicate that these two channels evolved from a 
common ancestral cation release channel in unicellular spe-
cies.  
 The evaluation of the phylogeny of these two channels 
suggests that RyRs arose from ancestral IP3R-like channels 
by incorporating promiscuous ‘RyR’ and ‘SPRY’ domains 
(so named because these sequence repeats were identified in 
both Dictyostelium discoideum tyrosine kinase Spore lysis A, 
splA and the mammalian RyR) via horizontal gene transfer. 
Indeed, the structure of the mammalian RyR1 has recently 
been solved showing that it is a member of the six trans-
membrane ion channel family [17]. Putative RyRs and IP3Rs 
have been also identified in unicellular organisms including 
Capsaspora owczarzaki, Salpingoeca rosetta, and Monosiga 
brevicollis as well as in pathogenic unicellular parasites in-
cluding Leishmania major, Leishmania infantum, Trypono-
soma cruzi, and Tryponosoma brucei [18, 19]. Though struc-
turally related, RyRs and IP3Rs have distinct physiologic 
and pharmacologic profiles [20]. 
RyRs 
 RyR is a member of the same gene family as IP3R, but 
has evolved specialized functions relevant to excitation-
contraction (E-C) coupling in striated muscles [21] and is 
developmentally regulated [2, 22].  
 RyR is a homotetramer comprised of four 565 kDa 
monomers [23], of approximately 5000 amino acids each 
[17]. There are three subtypes of RyRs in mammalian tis-
sues: RyR1 and RyR2 are required for skeletal muscle and 
cardiac E-C coupling, respectively [21, 24], and are also ex-
pressed in various non-muscle tissues [5, 25]; RyR3 was 
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originally identified in the brain [26] but exhibits an ubiqui-
tous expression, as it is widely expressed in other non-
neuronal tissues [27]. 
 RyR was named based on its purification using the high 
affinity plant alkaloid ryanodine [28], an agent known to 
profoundly alter SR Ca2+ release events [29]. When bound to 
RyR at low concentrations ryanodine locks the channel in a 
half open state, thereby resulting in depletion of Ca2+ from 
the SR and subsequent interruption of E-C coupling. This 
explains the historical use of extracts from the Ryania plant 
family by natives of South and Central America as poison 
for arrowheads: indeed the release of SR Ca2+ via the locked 
open RyRs causes tetany, and at high concentrations ryano-
dine blocks the channel [28]. RyR is normally closed at low 
cytosolic [Ca2+] (~100–200 nM); at submicromolar cytosolic 
[Ca2+], Ca2+ binds to high-affinity binding sites on RyR in-
creasing its open probability (Po). Channel activity is maxi-
mal at cytosolic [Ca2+] ~10 μM while elevating cytosolic 
[Ca2+] beyond this point leads to a reduction in Po [30, 31]. 
 We recently solved by single-particle cryo-electron mi-
croscopy the structure of RyR1 [17], demonstrating that it 
adopts a four-fold symmetric mushroom-like superstructure, 
with the large ‘cap’ (about 80% of the mass) located in the 
cytosol and the ‘stalk’ embedded in the ER/SR membrane, 
with six transmembrane helices (S1-S6) per protomer sur-
rounding the central pore [17]. Each protomer is built around 
an extended scaffold of alpha-solenoid repeats which include 
an aminoterminal, a bridging, and a core solenoid. At the 
extreme outer corners of the tetramer there are three SPRY 
domains and two pairs of RyR repeats, RY12 and RY34, the 
latter containing a regulatory protein kinase A (PKA) phos-
phorylation site. The RyR1 pore domain most closely resem-
bles that of the voltage-gated sodium channel (NavAB) and 
presents a single cytosolic constriction in the ion conduction 
pathway, at the S6 bundle crossing [17]. Glycine residues in 
the pore-lining helices may operate as “hinges” to facilitate 
the orientation of the cytoplasmatic extension of S6 in order 
to modulate the aperture of the channel. Notably, Gly4934 is 
conserved in all RyR isoforms and in IP3R. 
RyR Macromolecular Complex 
 The large and complex structure of RyR contains func-
tion-modifying phosphorylation sites and protein-binding 
domains, providing an attractive target for disease interven-
tion. The high-resolution structure of native RyR1 revealed 
the complete domain structure of the channel in unprece-
dented detail [17]. RyRs are macromolecular signaling com-
plexes, in which multiple proteins bind to a domain of the 
channel modulating its function [21, 32].  
 The Ca2+ stabilizing proteins calstabin1 (calcium channel 
stabilizing binding protein1, previously known as FKBP12) 
and calstabin2 (FKBP12.6) are peptidyl-propyl-cis-trans 
isomerases that associate via amphiphilic ?-sheet structures 
with RyR1 and RyR2, respectively, such that one calstabin 
protein is bound to each RyR monomer [33-35], in order to 
regulate the channel gating through protein-protein interac-
tions [36] and prevent pathological intracellular Ca2+ leak 
[37, 38]. Calstabin1 and calstabin2 differ at only 18 positions 
out of 108 residues. 
 We identified the calstabin-binding loop as part of the 
aminoterminal subdomain of the bridging solenoid [17]. Cal-
stabin binding may rigidify the interface between such sub-
domain with SPRY1-2, thereby stabilizing the connection 
with the cytosolic regulatory domains and eventually altering 
the relative orientation of these domains [17]. Highly con-
served leucine-isoleucine zipper motifs in RyR2 form bind-
ing sites for adaptor proteins that mediate binding of other 
proteins [32, 39], including kinases (e.g. PKA [40, 41], 
CaMKIIdelta [42]) and phosphatases (e.g. PP1 and PP2A). 
Specifically, the adaptor protein mAKAP mediates the bind-
ing of PKA and phosphodiesterase PDE43, whereas PP1 and 
PP2A are targeted to RyR2 via spinophilin and PR130, re-
spectively [43, 44]. All of the above mentioned proteins 
regulate the phosphorylation-dephosphorylation of RyR2 in 
Ser2809 (Ser2808 in mouse) [45] in response to stress [45-48]. 
Other channels are also regulated by stress signals, including 
the voltage-gated Ca2+ channels [49]. RyR function is also 
affected by oxidation, nitrosylation, and other post-
translational modifications [5, 41, 45, 47, 50]. Many other 
modulatory proteins complex directly and indirectly with 
RyR, including sorcin [51], calmodulin [52], homer [53], 
histidine-rich Ca2+ binding protein [54], S100A1 [55], triadin 
[56], junctin [57], and calsequestrin [58]. 
IP3Rs 
 IP3R channels are homo or heterotetramers composed of 
four subunits (approximately 300,000 Da each). The struc-
ture of the IP3R monomer comprises a ligand-ligand pocket 
at the amino terminus, a central cytosolic regulatory domain, 
and a pore region containing six transmembrane helices 
forming the Ca2+ channel region located at the carboxy ter-
minus [57, 59].  
 Three forms of IP3Rs (types 1, 2 and 3) have been char-
acterized [60-63]. Virtually all cell types have at least one 
form of IP3R, and many express all three types. Addition-
ally, the subcellular distribution of the three isoforms is cell-
type dependent [64]. IP3R1 has a broad tissue distribution 
but is especially abundant in the cerebellum, where it was 
initially purified and characterized [65]. It is also expressed 
in vascular smooth muscle cells, thyroid, uterus, and lym-
phocytes [20, 66, 67]. IP3R2 is expressed in cardiac muscle, 
as well as liver, kidney, and other epithelial tissues [68], 
while IP3R3 is expressed in endothelial cells, testis, endo-
crine and exocrine pancreas, spleen, gastrointestinal tract, 
and thymus [69]. 
 IP3R function is regulated by at least two major cellular 
signaling pathways: the second messenger inositol 1,4,5-
trisphosphate (IP3) [70], produced primarily by phospholipase 
C (PLC) metabolism of phosphoinositol-4,5-bisphosphate 
(PIP2) in response to the stimulation of G-protein-coupled 
receptors (GPCRs) or receptor tyrosine kinases [1, 71, 72], 
and phosphorylation by non-receptor tyrosine kinases [73]. 
IP3R Macromolecular Complex 
 Numerous signaling molecules bind to IP3R regulating 
its function, including Bcl-2, calmodulin [74], caldendrin 
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[75], carbonic anhydrase-related protein (CARP) [76], an-
kyrin [77], homer [78], and IP3R-binding protein released by 
IP3 (IRBIT) [79]. Studies in murine T-cells demonstrated 
that the BH4 domain of Bcl-2, which distinguishes anti- 
from pro-apoptotic members in the Bcl-2 family, is neces-
sary and sufficient in binding to IP3Rs, inhibiting apoptosis 
[80]. The binding of Bcl-2 to IP3R promotes low-amplitude 
oscillatory Ca2+ signals and inhibits high-amplitude sustained 
elevations that are instead associated with cell death [81]. 
Intriguingly, a Bcl-2 binding site has been recently identified 
also in RyR2 [82]. CARP has been shown to bind IP3R1 
causing conformational changes of the channel that reduce 
its affinity towards IP3 [76]. IRBIT suppresses the activation 
of IP3R by competing with IP3, acting as an endogenous 
pseudoligand whose inhibitory activity can be modulated by 
its phosphorylation status [83]. Moreover, the IP3R structure 
undergoes major conformational changes under influence of 
Ca2+ [84].  
 Various kinases, including CaMKII, Fyn, PKA PKG, and 
PKC, have been shown to phosphorylate IP3R [73, 85, 86]. 
We demonstrated that PKA and the phosphatases PP1 and 
PP2A are active components of the IP3R1 macromolecular 
complex [86]. A physical association between IP3R1 and 
calstabin1 had also been proposed [87] but subsequent stud-
ies have not been able to observe the formation of such inter-
action, despite detecting RyR1/calstabin1 complexes in par-
allel experiments [88, 89].  
HEART 
 Ca2+ is vital for the proper functioning of a healthy heart, 
as it is mechanistically involved in both myocardial contrac-
tile performance [90] and regulation of rhythmic beating 
[91]. Abnormalities in the regulation of Ca2+ homeostasis are 
associated with cardiovascular disorders including arrhyth-
mias, myocardial hypertrophy, and heart failure. Cardiac 
contraction is a tightly regulated process beginning with de-
polarization of the sinoatrial node, situated at the junction 
between the right atrium and the superior vena cava. This 
generates a wave of depolarization that travels throughout 
the atria, converging onto the atrioventricular node, and from 
there spreading throughout the ventricles. Ca2+ finely orches-
trates these processes, linking myocardial depolarization to 
myocardial contraction through E-C coupling [92]. Indeed, 
the rise in cytoplasmic [Ca2+] is critical for activation of ac-
tin-myosin cross-bridging, shortening of the sarcomere, and 
muscle contraction.  
Cardiac Excitation-Contraction Coupling 
 An Italian physician, Luigi Galvani, established in the 
18th century the relationship between electrical signaling 
and mechanical contraction conducting seminal experi-
ments in frog legs, pioneering bioelectricity [93]. In 1883 
Sidney Ringer was the first to discover that Ca2+ was a key 
component of cardiac contractility [6]. His observations 
were confirmed in 1913 by George Mines, who elegantly 
demonstrated that this specific ion was responsible for link-
ing excitation and contraction [94]. Subsequent studies 
confirmed that cardiac contractility is directly proportional 
to systolic cytosolic [Ca2+] [95, 96]. 
RyR2 and Heart Failure 
 Despite tremendous advances in the treatment of myo-
cardial infarction, heart failure (HF), and cardiac arrhythmias 
[97], cardiovascular disease remains the leading cause of 
death worldwide, causing ~600.000 deaths per year in the 
US alone [98-100]. HF is associated with significant im-
pairment in myocardial contractility, such that rates of both 
contraction and relaxation are slowed [101, 102].  
 RyR2 is responsible for Ca2+ release from the SR, where 
it is stored at high concentration (in the millimolar range), 
thereby raising the cytosolic [Ca2+] about ten-fold (from 
~100 nM to ~1 μM) with each heartbeat in order to activate 
cardiac muscle contraction. Abnormal intracellular Ca2+ han-
dling represents a major cause of decreased muscle contrac-
tion (systolic dysfunction) and defective relaxation (diastolic 
dysfunction) in patients with HF, as confirmed by reports of 
reduced Ca2+ transient amplitude, increased Ca2+ transient 
duration, prolonged Ca2+ transient decay time, and decreased 
SR Ca2+ load, leading to impaired contractility [44, 103]. The 
mechanistic role of diastolic Ca2+ leak through dysfunctional 
RyR2 in the pathophysiology of HF has been experimentally 
established for the first time in 2000 [44]. 
 RyR2 leak in HF is caused by stress-induced remodeling 
of the RyR2 macromolecular complex due to PKA hyper-
phosphorylation, oxidation, and nitrosylation of the channel, 
eventually resulting in an altered stoichiometry of the RyR2 
complex, with displacement of calstabin2 [41], phosphatases 
[104], and PDE4D3 [43] from the channel. Depletion of 
PDE4D3 and phosphatases results in elevated levels of cyclic 
adenosine mono-phosphate (cAMP) [43] and a decreased rate 
of dephosphorylation, thereby promoting further PKA hyper-
phosphorylation. The term PKA hyperphosphorylation de-
scribes RyR2 in which 3–4 of the four RyR2 monomers are 
chronically PKA phosphorylated. Hyperphosphorylated/cals- 
tabin2 depleted channels are sensitized to cytosolic Ca2+, lead-
ing to inappropriate Ca2+ release during diastole, referred to as 
a diastolic SR Ca2+ leak. Most recently, we demonstrated that 
intracellular Ca2+ leak via RyR2 plays a key role in mitochon-
drial Ca2+ overload and dysfunction in HF [105].  
 As part of the classical ‘fight-or-flight’ response stress 
pathway [45], sympathetic nervous system activation causes 
catecholamine release and ?-adrenergic receptor (?AR) 
stimulation, increasing the gain of E-C coupling system and 
enhancing contractility [106]. Binding of catecholamines to 
?ARs activates a G protein-coupled intracellular signaling 
cascade [107-110], leading to the activation of adenylyl-
cyclase with subsequent increased intracellular levels of 
cAMP, which in turn triggers PKA. RyR2 phosphorylation 
by PKA increases the Po of the channel by causing dissocia-
tion of the stabilizing protein calstabin2, resulting in in-
creased sensitivity of RyR2 to Ca2+-dependent activation [44, 
104].  
 Hyperactivation of sympathetic nervous system in HF is 
initially compensatory, but eventually accelerates the pro-
gression of the disease, posing severe toxicity on the chroni-
cally failing heart [107, 108, 111]. In this sense, the benefi-
cial effects of ?AR blockers and other therapeutic ap-
proaches that mitigate or protect the heart against this sym-
pathetic overdrive are well documented [108, 112, 113]. In-
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triguingly, the discovery of leaky RyR2 in HF [44] provides 
a compelling mechanism to explain the therapeutic efficacy 
of ?AR blockers in HF. Despite ?AR blockers represent a 
standard therapy in HF [108, 109], there is no accepted un-
derstanding of their exact mechanism of action in such a 
disease. In fact, multiple explanations have been suggested, 
including altered myocardial gene expression and increased 
?AR density [109, 114].  
 We demonstrated that systemic administration of ?AR-
blockers reduces PKA hyperphosphorylation of RyR2 and 
restores calstabin2 binding to RyR2 channels both in animal 
models of HF [115] and in cardiac samples from human 
heart transplant recipients [116]. We interpreted these find-
ings as indicating that in failing hearts ?AR-blockers can 
indirectly fix the leak in RyR2 channels by inhibiting PKA 
hyperphosphorylation of the channel. This hypothesis was 
confirmed by proving that ?AR-blockers can improve car-
diac function after MI in WT but not in RyR2-S2808D mice, 
in which Ser2808 of RyR2 is substituted with an aspartic acid 
residue, in order to mimic a constitutive PKA phosphoryla-
tion of the channel [41]. 
 Alternative mechanisms underlying SR Ca2+ leak in HF 
have been proposed, including phosphorylation of RyR2 by 
Ca2+/Calmodulin kinase II (CaMKII) at Ser2815 (Ser2814 in 
mouse) [117]. However, we developed genetically altered 
mice that harboring RyR2 channels that cannot be phos-
phorylated by CaMKII (RyR2-S2814A), demonstrating in 
vivo that they were not protected against post-myocardial 
infarction HF progression [42]. Moreover, CaMKII phos-
phorylation of RyR2 is required for the rate-related increase in 
contractility [42]. Indeed, CaMKII is activated by Ca2+ itself 
and is exposed to more Ca2+ at higher heart rates, thereby re-
sulting in increased CaMKII phosphorylation of RyR2, aug-
mented SR Ca2+ release, and increased contractility (Bowditch 
phenomenon, frequency-dependent inotropy, or treppe [118]). 
Thus, CaMKII activation during HF is related to HR, which in 
turn increases the integral of cytosolic [Ca2+] [42]. Addition-
ally, CaMKII has been demonstrated to be also activated by 
oxidation [119-121], and the role of oxidative stress in cardio-
vascular disease is well established [105].  
RyR2 and Cardiac Arrhythmias  
 Intracellular CRCs play a major role in arrhythmogenesis 
[43, 48, 122, 123]. Indeed, increased RyR2 activity causes 
atrial and ventricular arrhythmias, particularly associated with 
increased catecholaminergic stimulation [123-126]. Altered 
Ca2+ handling, as seen in HF, contributes to triggered activity 
arising from early after-depolarization (EAD) or delayed after-
depolarization (DAD). EAD occurs in the setting of increas-
ingly labile repolarization observed in HF, during phase 2 and 
phase 3 of the action potential. DAD occurs during phase 4 
and results from elevated intracellular Ca2+ load and spontane-
ous SR Ca2+ release, which leads to activation of transient in-
ward current.  
 Besides the acknowledged role in providing a substrate 
for arrhythmias in patients with HF or cardiac hypertrophy 
[43, 127], RyR2 has also been linked to at least two forms of 
sudden cardiac death (SCD): catecholaminergic polymorphic 
ventricular tachycardia (CPVT) [5, 128] and arrhythmogenic 
right ventricular dysplasia type 2 (ARVD2) [129]. Moreover, 
exon 3 deletion of RyR2 has been associated with left ven-
tricular noncompaction and CPVT [130]. 
 CPVT is a rare inherited form of exercise-induced SCD 
that occurs in typically young individuals with structural 
normal hearts [5]. Several mutations in RyR2 have been 
linked to CPVT [128]. RyR2s with most of CPVT mutations 
exhibit reduced affinity for calstabin2, which results in leaky 
channels during exercise [131]. Calstabin2 deficient and hap-
loinsufficient mice have CPVT and their RyR2 channels 
display slightly increased open probability at baseline that 
increases substantially following exercise [131].  
 ARVD is another inherited cardiac disorder characterized 
by substitution of the right ventricular myocardium with fi-
brofatty tissue, which appears to be a result of progressive 
death of cardiomyocytes resulting from a combination of 
inflammation and apoptosis [132, 133]. Twelve different 
types of ARVD have been identified hitherto, and type 2 is 
caused by mutations in RyR2 [134]. Clinical presentation of 
ARVD is characterized by arrhythmias of right ventricular 
origin, ranging from premature beats to ventricular fibrilla-
tion, often leading to SDC [135]. Similar to CPVT, ARVD 
patients also exhibit exercise- and adrenergic-induced fatal 
arrhythmias. Available therapy for both CPVT and ARVD 
remain limited, and implantable cardioverter/defibrillator 
remains the best choice [133, 136]. We have shown that 
pharmacological stabilization of RyR2 prevents intracellular 
Ca2+ leak and arrhythmias [137], providing a promising po-
tential therapeutic option for these disorders.  
 Most recently, we and others have also demonstrated that 
leaky RyR2s are key players in the pathophysiology of atrial 
fibrillation (AF) [123, 124, 138]. We proved that atrial 
RyR2s from patients with chronic AF were oxidized, phos-
phorylated and depleted of calstabin2 [123]. Likewise, mice 
with intracellular Ca2+ leak exhibited increased atrial RyR2 
oxidation, mitochondrial dysfunction, ROS production and 
AF susceptibility. Interestingly, AF could be prevented by 
inhibition of mitochondrial ROS generation and by pharma-
cological treatment of RyR2 leak [123], indicating that mito-
chondrial oxidative stress and alterations in RyR2 may form 
a vicious cycle in the development of AF.  
IP3Rs and Cardiac Disease 
 The role of IP3Rs in the heart remains quite controversial 
[105, 139]. Within cardiac myocytes, IP3R mRNA levels are 
~50-fold lower than that of the cardiac RyR mRNA [140]. 
The relative amount of IP3Rs is too low and the kinetics of 
Ca2+ release from IP3Rs is too slow compared with RyRs to 
contribute to the Ca2+ transient during E-C coupling. Besides, 
Ca2+ flux via RyR has been shown to be markedly larger than 
the flux through IP3R [141, 142]. 
 The study of IP3-induced Ca2+ release in cardiomyo-
cytes has been difficult because Ca2+ release from RyR2, 
required for E-C coupling, dominates in the heart [105]. 
Indeed, direct studies of Ca2+ release in response to IP3 in 
cardiac preparations have revealed Ca2+ responses that are 
of much lower magnitude than those seen with the RyR 
system [143]. Likewise, direct generation of IP3 in intact 
non-beating neonatal cardiomyocytes does not alter cytoso-
lic free Ca2+ [144].  
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 IP3Rs are more abundant in atrial than in ventricular car-
diomyocytes and even more abundant in conduction tissue 
cells [145, 146]. Atrial and ventricular tissue express a simi-
lar proportion of IP3R1 and IP3R2 [145]; however, studies 
in isolated cardiomyocytes revealed that IP3R2 is clearly the 
predominant isoform in contractile myocardial cells and in 
sinoatrial node [147], whereas IP3R1 is the predominant iso-
form in other cell types, including endothelial cells and Purk-
inje fibers [145, 146]. In adult rabbit ventricular myocytes, 
IP3Rs were implicated in the regulation of gene expression, 
based on the finding that the endothelin 1–induced mobiliza-
tion of Ca2+ from the nuclear envelope was blocked by 2-
aminoethoxydiphenyl borate (2-APB) [148], which is though 
considered a reliable blocker of store-operated Ca2+ entry but 
an inconsistent inhibitor of IP3-induced Ca2+ release [149].  
 In summary, most studies are in agreement that activation 
of IP3Rs does not significantly contribute to cardiac E-C cou-
pling. A functional role for these channels has been also pro-
posed in the pathophysiology of cardiac arrhythmias as well as 
myocardial hypertrophy [150]. Indeed, a significant upregula-
tion of IP3Rs mirrored by enhanced channel activity [151] has 
been observed in patients with chronic atrial fibrillation [152], 
which remains the most common sustained arrhythmias, af-
fecting 2.3 million adults in the US [98, 153, 154]. A reduc-
tion of sustained arrhythmias after application of 2-APB has 
also been reported [155]. Moreover, increased IP3 generation 
in the heart has been associated with the induction of ventricu-
lar arrhythmias [156]. A marked increase in IP3 levels in the 
heart occurs during early post-ischemic reperfusion following 
activation of ?1AR or thrombin receptor and correlates tempo-
rally with the development of ventricular tachycardia and fib-
rillation [156]. Of interest, inhibition of PLC-induced IP3 gen-
eration prevents reperfusion-related arrhythmias [157].  
 IP3Rs have been indirectly implicated in the develop-
ment of left ventricular hypertrophy via upstream signaling 
pathways coupled to IP3, including ?1AR, angiotensin II, 
and endothelin-1. However, several studies have demon-
strated a main role for diacylglycerol (the other product re-
sulting from PLC hydrolysis) and subsequent PKC activa-
tion, more than a direct IP3R activation, in the induction of 
cardiac hypertrophy [158-160].  
SKELETAL MUSCLE 
 Depolarization of skeletal myocytes involves a protein-
protein interaction [161] across the junctional cleft between 
the dihydropyridine receptor (Cav1.1) on specialized invagi-
nations of the sarcolemma (transverse tubules) and RyR1 on 
the SR membrane (terminal cisternae) [162]. Ergo, Cav1.1 
acts as a marionettist on RyR1, eventually leading to Ca2+ 
release from the SR.  
 Remarkably, RyRs were initially observed in skeletal 
muscle, visualized in electron micrographs as large electron-
dense masses located along the face of the SR terminal cis-
ternae, which is closely apposed to transverse tubule mem-
branes to form a structure named triad junction [163]. There-
fore, the RyRs were initially termed triad junctional foot 
proteins [164, 165]. Noda and colleagues provided the in 
vivo evidence for a functional role of RyR1 in E-C coupling, 
engineering a mouse lacking exon 2 of RyR1 and demon-
strating that such a model exhibits severe skeletal muscle 
abnormalities and dies perinatally due to respiratory failure 
[166]. Subsequent ultrastructural studies of hindlimb and 
diaphragm muscles demonstrated the absence of RyR1-
Cav1.1 complexes [167], which are essential for a proper E-
C coupling in the skeletal muscle [168]. 
 RyR1 dysfunction has been described in both inherited 
and acquired muscle disorders [169, 170]. Malignant hyper-
thermia (MH) and central core disease (CCD) represent the 
best examples of RyR1 channelopathies in the skeletal mus-
cle [171].  
Role of RyR1 in Malignant Hyperthermia and Central 
Core Disease  
 MH is a pharmacogenetic disorder, inherited in an auto-
somal dominant fashion and continues to be of major con-
cern for anesthetic-induced deaths in otherwise healthy indi-
viduals [172]. MH episodes are typically rapid and severe, 
reaching core body temperatures of 43°C, leading to organ 
failure and death if not rapidly treated. The exact prevalence 
of MH susceptibility is difficult to determine since the syn-
drome only becomes apparent after exposure to triggering 
agents including volatile anesthetic agents such as halothane, 
isoflurane, sevoflurane, desflurane, enflurane and the neuro-
muscular blocking agent succinylcholine [173]. Susceptibil-
ity can be determined in vitro by measuring the contractile 
response to caffeine or halothane in biopsied muscle fibers. 
A related syndrome referred to as porcine stress syndrome is 
found in certain lines of domestic swine where stressed pigs 
undergo stress-induced hyperthermia [174].  
 These disorders are thought to develop following extreme 
skeletal muscle contraction that results from excess Ca2+ in 
the myoplasm following anesthesia in humans or during 
stress in pigs; this Ca2+ overload causes sustained contrac-
tions, which accounts for the rapid onset of muscle rigidity, 
leading to an augmented metabolic demand on myocytes, 
which depletes ATP levels. Myocytes respond by increasing 
ATP production via oxidative phosphorylation and glycoly-
sis, and such a prolonged hypermetabolic state generates 
heat. Alterations in 3H-ryanodine binding properties in por-
cine MH samples provided evidence linking RyR1 dysfunc-
tion to the disease [175], which was later confirmed by bio-
physical experiments [176].  
 CCD is a dominantly inherited congenital myopathy, first 
described in 1956 [177]. The name derives from the typical 
appearance of the biopsy on light microscopy, where the 
muscle cells have metabolically inactive tissue in the center 
of type I myofibers, appearing as cores that are devoid of 
mitochondria and specific oxidative enzyme stains. Common 
symptoms include hypotonia, delayed motor milestones, and 
skeletal abnormalities including congenital hip dislocation 
and scoliosis.  
 There is no clear division between MH and CCD and 
some RyR1 mutations have been linked to a combined MH 
and CCD phenotype [178]. Notably, most MH mutations in 
RyR1 gene lead to a gain-of-function effect, with increased 
sensitivity to channel agonists, causing a leak in RyR1 
channels, whereas most CCD-related mutations have been 
associated with channels displaying reduced conductance 
[179].  
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 Importantly, the mutated codons giving rise to MH and 
CCD tend to cluster in three specific regions of the RyR1 
gene, that correspond to the following domains in the amino-
acidic sequence: regions 1 (C35–R614) and 2 (D2129–
R2458) reside in the myoplasmic foot domain of the protein, 
whereas region 3 (I3916–G4942) is located in the transmem-
brane/luminal region of the highly conserved carboxy-
terminal domain, important for allowing Ca2+ flux through 
the channel [17].  
 Mutations in RyR1 are also associated with other rare 
CCD-related congenital myopathies including centronuclear 
myopathy, multi-minicore disease, Samaritan myopathy, 
congenital fiber-type disproportion, and nemaline myopathy 
[180-182]. 
Role of RyRs1 in Muscular Dystrophy  
 We established that intracellular Ca2+ leak via RyR1 rep-
resents an essential feature of different forms of muscular 
dystrophy (MD), including Duchenne MD [183] and limb-
girdle (or Erb’s) MD [169]. Specifically, RyR1 from a 
Duchenne MD murine model (mdx mouse) was excessively 
cysteine nitrosylated and depleted of calstabin1, leading to 
increased spontaneous RyR1 openings and overall reduced 
specific muscle force [183]. Similar findings were obtained 
when evaluating RyR1 in ?-sarcoglycan-deficient mice, an 
established model of limb-girdle DM [169].  
 Thus, we demonstrated common mechanisms of mal-
adaptation of RyR1, including post-translational modifica-
tions of the channel and dissociation of the stabilizing 
subunit calstabin1, in two major disorders that weaken the 
muscular system hampering locomotion and that remain vir-
tually without effective pharmacological treatment. We 
proved in both cases that stabilizing the RyR1-calstabin1 
association ameliorated muscle function [169, 183], thereby 
providing an innovative therapeutic target and potential op-
tions for the treatment of DM.  
 In conditions of strenuous muscular stress or in a disease 
such as HF, both of which characterized by chronic activa-
tion of the sympathetic nervous system and increased pro-
duction of reactive oxygen and nitrogen species [108, 184, 
185], skeletal muscle function is impaired, possibly due to 
altered E-C coupling. Indeed, the amount of Ca2+ released 
from the SR during each contraction of the muscle is re-
duced, Ca2+ reuptake is slowed, and aberrant Ca2+ release 
events can occur [40, 186].  
 We have shown in both an animal model as well as in 
exercising humans that chronic ?AR stimulation and deple-
tion of calstabin1 from RyR1 plays a mechanistic role in the 
contractile failure and muscle fatigue, defined as decline in 
ability of a muscle to generate force, observed during sus-
tained exercise [187]. Consistent with these observations, we 
have demonstrated that the remodeling of RyR1 plays a piv-
otal role also in sarcopenia and muscle aging [47] and we 
were able to prevent RyR1 dysfunction and ameliorate skele-
tal muscle function in aging by genetically enhancing mito-
chondrial antioxidant activity [188], as extensively discussed 
in the dedicated section of this overview. 
 Since skeletal muscle dysfunction, as seen in HF or mus-
cular disorders, remains practically without effective treat-
ment, drugs that restore RyR Ca2+ release function, represent 
promising candidates. In this sense, these drugs could be 
ideal in conditions with co-morbidity between cardiac and 
skeletal muscles. Indeed, as muscular RyR1 undergoes post-
translational modifications in HF [40, 186], remodeling of 
the cardiac RyR2 has been also reported in mouse models of 
Duchenne MD, triggering ventricular arrhythmias [50]. 
IP3Rs and Muscle Pathophysiology 
 In contrast to the acknowledged prominent role of RyR1, 
there is no strong experimental evidence for a significant 
functional action of IP3R-mediated Ca2+ release in adult 
muscle fibers. Immunodetectable IP3Rs and specific 
[3H]IP3–binding sites were reported to be preferentially ex-
pressed in slow oxidative (type I) and fast oxidative glyco-
lytic (type IIA) fibers [189]. The presence of IP3Rs has been 
later confirmed in both rabbit and mouse skeletal muscle 
[190]. Most recently, the expression of the three isoforms has 
been investigated in adult murine skeletal muscle, revealing 
that IP3R1 is absent in slow-type muscle fibers and is ex-
pressed preferentially in fast, mixed metabolism (type IIX) 
fibers whereas IP3R2 and IP3R3 are ubiquitously expressed 
in all muscle fiber types [191].  
 Although IP3Rs have been shown to be present and func-
tional in cultured muscle cells [192, 193], no significant 
change in Ca2+ signal has been detected in adult muscle fi-
bers after IP3 microinjection or photolysis of membrane-
permeant IP3 [194]. Available data seem to converge to-
wards a potential role of IP3Rs in neuromuscular junctions 
and in satellite cells [195]. 
CENTRAL NERVOUS SYSTEM 
 Ca2+ signaling regulates numerous neurological processes 
including synaptic transmission, secretion, excitability, 
learning, and memory. Emerging evidence suggests that sev-
eral types of neurological disorders may share a common 
underlying mechanism, i.e. altered Ca2+ release from the ER 
[196-199]. The involvement of IP3Rs and RyRs in neurode-
generative disease relies at least in part on abnormal Ca2+ 
signaling that ultimately leads to excitotoxicity in specific 
areas of the central nervous system [200].  
Intracellular CRCs and Amyotrophic Lateral Sclerosis  
 Amyotrophic lateral sclerosis (ALS), also known as Lou 
Gehrig’s disease, is a rapidly progressing disease character-
ized by upper and lower motor neuron degeneration, eventu-
ally resulting in muscle atrophy and weakness throughout the 
body [201-203]. The current knowledge of its causes is very 
limited and it seems to derive from multiple and complex 
environmental factors and genetic predisposition [204, 205].  
 The most studied gene associated with ALS susceptibility 
is the copper-zinc superoxide dismutase [206, 207]. Several 
investigators have proposed an autoimmune origin for ALS 
[208, 209]. Supporting this view, Pagani and colleagues 
demonstrated that IgG isolated from ~50% of ALS patients 
can increase Ca2+ levels in motor nerve terminals in murine 
tissue cultures, enhancing spontaneous neurotransmitter re-
lease at neuromuscular junctions [210]. Of interest, both RyR 
and IP3R were necessary to maintain the IgG-dependent en-
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IP3R were necessary to maintain the IgG-dependent en-
hancement of neurotransmitter release [210].  
 Most recently, a genome-wide association study unveiled 
IP3R2 gene as a potential player in sporadic ALS, identifying 
a specific mutation (rs2306677) in intron 42 of IP3R2 gene 
[211]. IP3R2 is a very plausible susceptibility gene for ALS 
since it is involved in glutamate-mediated neurotransmission, 
is one of the main regulators of intracellular Ca2+ concentra-
tions, and is an important player in apoptosis [211].  
 The role of RyRs in ALS pathophysiology has been less 
studied. Intriguingly, an imbalance between RyR and cal-
stabin in spinal cords of neurological controls and patients 
with motor neuron disease has been reported in a Japanese 
study, revealing a significantly decreased expression of cal-
stabin in neurons from patients with ALS [212]. Moreover, 
dantrolene sodium, a myorelaxant currently used to treat 
malignant hyperthermia, neuroleptic malignant syndrome, 
spasticity and Ecstasy (3,4-methylenedioxy-metamphetamine, 
MDMA) intoxication, had been proposed as potential ther-
apy for ALS [213]. Of note, even though dantrolene is gen-
erally labeled as ‘RyR inhibitor’, a precise mechanism of 
action has not been identified and several investigators have 
demonstrated that the RyR2 isoform is not a target of such a 
drug [214, 215]. Recently, Laver and colleagues reported 
that calmodulin is essential for dantrolene action [216]: its 
absence in single RyR assays might therefore explain why 
this drug does not inhibit RyR in lipid bilayer preparations. 
Intracellular CRCs and Alzheimer’s Disease  
 Alzheimer’s disease (AD) is the most common type of 
dementia, characterized clinically by progressive deteriora-
tion of cognitive functions including memory, reasoning, and 
language. Ca2+ certainly plays a pivotal role in the patho-
genesis of the disease. Indeed, altered Ca2+ signaling has 
been detected in brain cells from both AD patients and ani-
mal models of AD, even before the appearance of amyloid 
A?-plaques or tangles, considered pathological hallmark 
features of AD [217, 218]. Whether A?-plaques are a cause 
or a consequence of AD remains controversial.  
 According to Demuro and Parker cytotoxicity of A?-
amyloid oligomers involves Ca2+ release from the ER via 
activation of IP3Rs, as demonstrated in vitro in Xenopous 
oocytes [219]. Supporting this view, studies in fibroblasts 
isolated from patients with familial AD revealed that prese-
nilins activate IP3Rs potentiating Ca2+ release from the ER 
[220]. These results have been confirmed in other cell types. 
Abnormal Ca2+ homeostasis in AD is further amplified by the 
increased A?-amyloid production caused by IP3R activation 
[221], in a vicious cycle that ultimately leads to cell death.  
 Most recently, Foskett demonstrated that an exaggerated 
Ca2+ signaling mediated by IP3R1 contributes to AD patho-
genesis [222]. On the other hand, several reports have shown 
alterations of expression and function of RyRs in different 
murine models of the disease, in human AD-affected brains, 
and in cells expressing familial AD-linked mutations on the 
?-amyloid precursor protein and presenilins [223-225]. 
Moreover, altered RyR2 expression has been reported in a 
study of the whole-genome expression profile of sporadic 
and monogenic early-onset AD [226]. Available data suggest 
that alterations in RyR-mediated Ca2+ handling are associated 
to AD etiopathogenesis through means of various mecha-
nisms, including the regulation of A?-amyloid production, 
synaptic function, memory and learning abilities, and neu-
ronal death [227]. 
Intracellular CRCs and Huntington’s Disease  
 Huntington’s disease (HD) is a dominantly inherited ge-
netic disorder characterized by dementia, slowly progressing 
movement disorders and psychiatric symptoms [228]. It is 
caused by an exaggerated polyglutamine expansion in the 
aminoterminus of the huntingtin protein. Mutant huntingtin 
impairs both protein folding and protein degradation. Inter-
estingly, mutant huntingtin has been reported to disrupt Ca2+ 
signaling by forming a complex with the NMDA receptor 
and synapse-associated protein 90 (SAP-90) [229]. Addi-
tionally, huntingtin can bind and activate IP3R1 and impair 
mitochondrial function [230]. Consistent with these findings, 
the exogenous expression of the human mutant huntingtin in 
Drosophila melanogaster led to retinal degeneration, which 
was prevented by knocking-down IP3R1 [231]. 
Intracellular CRCs and Post-Traumatic Stress Disorder  
 Post-traumatic stress disorder (PTSD) presents with a 
diverse set of symptoms involving a mixture of psychologi-
cal, social, and biological processes [232]. Neurobiological 
research did not clarify a clear mechanism underlying the 
disease, but overall, there is mounting evidence that symp-
tomatology following experiences of traumatic stress may 
derive from effects on brain function and structure [232]. 
Current therapy for PTSD remains largely supportive, and 
not mechanism-based.  
 Using chronic restraint to induce stress in mice we re-
cently demonstrated that hippocampal RyR2s of stressed 
mice were phosphorylated by PKA, oxidized and nitrosy-
lated, inducing intracellular Ca2+ leak [46]. The mice also 
exhibited impaired cognitive performance in various behav-
ioural tests, including the Morris water maze, which are 
known to depend on hippocampal function. Pharmacologic 
or genetic inhibition of the leak prevented the cognitive dys-
function [46]. Since stress-induced cognitive impairment 
shares many features with PTSD [233], the pathway that we 
elucidated could be a potential therapeutic target. The link 
between PTSD and ER Ca2+ has been also confirmed in the 
rat, validating a functional role for ER stress and apoptosis in 
the pathophysiology of the disease [234]. 
Intracellular CRCs and Spinocerebellar Ataxias  
 Spinocerebellar ataxias (SCA) are a group of genetic 
movement disorders characterized by progressive ataxia and 
cerebellar atrophy [235]. Since cerebellar Purkinje cells ex-
press high levels of IP3R1, this channel has been proposed as 
a key player in cerebellar long-term depression generation, 
which protects neuronal Purkinje cells against high gluta-
mate stimulation [236].  
 Several types of SCA are caused by mutations that gen-
erate poliglutamine proteins, such as ATXN2 [237] and 
ATXN3 [238], which have been shown to bind IP3R1, po-
tentiating ER Ca2+ release. Moreover, deletions of different 
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regions of IP3R1 gene have been linked to other types of 
SCA, not associated with polyglutamine repeats [239, 240]. 
A profound derangement in IP3R1-dependent Ca2+ signaling 
has been also reported in the opisthotonos mouse, which is 
ataxic and convulsive [241]. 
METABOLISM 
 Mounting evidence indicates that changes in intracellular 
[Ca2+] play a pivotal role in glucose homeostasis, modulating 
both insulin secretion from the pancreatic islets of Langer-
hans and insulin resistance in peripheral responses of liver, 
muscle and adipocytes [5, 242-245].  
 Several studies have demonstrated that altered cellular 
Ca2+ homeostasis is a key contributor to impaired beta cell 
function and survival in type 2 diabetes mellitus (T2DM) 
[246, 247]. However, according to the classical view of the 
glucose sensing machinery, insulin secretion largely depends 
on the depolarization of the plasma membrane and the sub-
sequent voltage-activated Ca2+ influx from the extracellular 
space [248, 249].  
 Most recently, we established both in humans and animal 
models [5] the mechanistic role of Ca2+ mobilization from 
the ER via RyR2 in insulin secretion, a topic that had re-
mained controversial for decades. In fact, while the expres-
sion of IP3R1 [250, 251] and RyR2 [252-254] had been re-
ported in pancreatic beta cells, their functional role had not 
been fully dissected heretofore.  
Intracellular CRCs and Glucose Homeostasis 
 A seminal study revealed that mice with double knockout 
of IP3R2 and IP3R3 are lean and hypoglycemic despite a 
normal caloric intake, most likely as a result of difficulty in 
nutrient digestion, and exhibit severe impairment in Ca2+ 
signaling and secretion in acinar cells of the exocrine tissues 
[255]. Moreover, variations within IP3R3 had been identified 
as a risk factor for type 1 diabetes mellitus (T1DM) in hu-
mans [256]. However, a subsequent study based on a family-
based approach, which is not subject to population stratifica-
tion, did not confirm an obvious role of genetic variation of 
the IP3R3 gene in T1DM risk [257].  
 A demonstration of a connection between glucose-
stimulated insulin secretion and Ca2+ signaling through IP3-
sensitive Ca2+ stores comes from mice heterozygous for the 
anx7 gene, which encodes for Ca2+-activated GTPase sup-
porting Ca2+ channel activities [258]. These mice exhibit 
defects in IP3R expression, and Ca2+ signaling in panreatic 
islets, and impaired insulin secretion [258]. Moreover, PKA-
mediated promotion of Ca2+-induced Ca2+ release via IP3Rs 
has been implicated as part of the mechanism by which 
cAMP amplifies insulin secretion [259].  
 The potential involvement of RyR2 in insulin release has 
been suggested by in vitro experimental data showing an 
enhanced Ca2+ response in beta cells following caffeine 
treatment [260]. RyRs had been proposed to be located on 
insulin granules [261] but Polonsky and colleagues subse-
quently demonstrated that RyRs do not co-localize with se-
cretory granules [252]. Additionally, the finding that genetic 
deletion of the RyR2 subunit calstabin2 induces impaired 
glucose-induced insulin secretion in mice suggests a func-
tional role for RyR2 in glucose homeostasis [262].  
 We exploited rare RyR2 mutations identified in patients 
with CPVT to assess RyR2 function in beta cell dynamics. 
We discovered that CPVT patients with mutant leaky RyR2 
present with glucose intolerance [5]. In mice, transgenic ex-
pression of CPVT-associated mutated RyR2 resulted in im-
paired glucose homeostasis, and an in-depth evaluation of 
pancreatic islets and beta cells from these animals revealed 
intracellular Ca2+ leak via oxidized and Cys-nitrosylated 
RyR2 channels, depleted intracellular Ca2+ stores, activated 
ER stress response, mitochondrial malfunction, and de-
creased fuel-stimulated insulin release [5].  
 We also verified the effects of pharmacological inhibition 
of intracellular Ca2+ leak in CPVT-associated RyR2-
expressing mice, in human islets from diabetic patients, and 
in an established murine model of T2DM [5]. Our results 
suggest a scenario in which the chronic ER Ca2+ leak via 
RyR2 triggers ER stress and mitochondrial dysfunction in 
pancreatic beta cells, causing a bioenergetic deficit with de-
creased ATP synthesis, thereby impairing metabolism-
secretion coupling. These findings raise the possibility that 
the relationship between diabetes and cardiovascular disor-
ders may be more complex than previously appreciated: in-
deed, diabetes, which is a critical risk factor for the devel-
opment of cardiovascular disease [263], can also represent a 
sequela of heart disease, especially considering that RyR2 
channels are chronically leaky in HF [264]. 
 Ca2+ handling plays a key role in the regulation of glu-
cose homeostasis also in the liver, as evidenced by the ob-
servations that glucagon and cAMP can increase [Ca2+], 
promoting gluconeogenesis, while Ca2+ chelation blocks it 
[265]. We have demonstrated that IP3R1 mediates the fast-
ing-mediated activation of CaMKII in hepatocytes [266]. 
Moreover, PKA-dependent phosphorylation of IP3R1 has 
been shown to increase cytosolic [Ca2+], leading to increase 
in the phosphatase activity of calcineurin and the subsequent 
dephosphorylation of the cAMP response element-binding 
protein (CREB)-regulated transcription coactivator 2 
(CRTC2), thereby resulting in the induction of glu-
coneogenic gene expression [267]. On the other side, insulin-
dependent phosphorylation of IP3R1 by AKT inhibits Ca2+ 
mobilization and CRTC2 dephosphorylation, resulting in the 
suppression of gluconeogenesis [267]. An intriguing role for 
both RyR and IP3R in the regulation of insulin signaling has 
been reported in skeletal muscle primary cultures. Specifi-
cally, insulin promotes RyR1 S-glutathionylation and subse-
quent RyR1-mediated Ca2+ release; in parallel, insulin stimu-
lates IP3 generation and activation of IP3R-mediated Ca
2+ 
release [268]. These two signaling pathways have been 
shown to contribute to the net gain in surface GLUT4 levels 
elicited by insulin [268], increasing glucose uptake [269].  
AGING 
 A well-established hallmark of aging is the progressive 
decline in muscle function, characterized by loss of muscle 
mass and reduced force generating capacity [109]. Progres-
sive development of muscle dysfunction has been described 
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not only in mammals [270, 271] but also in the nematode 
Caenorhabditis elegans [272, 273].  
 E-C uncoupling is considered a major factor in age-
dependent decline in muscle contraction. Indeed, reduced SR 
Ca2+ release has been elegantly demonstrated in aged rat gas-
trocnemii [274], without any significant effect on RyR1 lev-
els [275]. A subsequent study, while confirming no overall 
effect of age (2-year-old rats) on RyR1 expression in the 
skeletal muscle, revealed a significant decrease in calstabin1 
levels [276].  
 We recently proved that RyR1 in muscle become pro-
gressively oxidized, nitrosylated, and depleted of calstabin1, 
resulting in leaky channels, reduced tetanic Ca2+, decreased 
muscle specific force and impaired exercise capacity [47]. 
To confirm that leaky RyR1 causes the defects in function 
observed in aged muscle we generated a leaky RyR1 model 
(RyR1-S2844D mouse), which mimics a constitutively 
phosphorylated state of the channel; we also investigated 
muscle specific calstabin1 deficient mice. Both strains pre-
maturely develop a skeletal muscle phenotype similar to that 
observed in 24-month-old WT mice [47].  
 We provided evidence for a direct role of mitochondrial 
free radicals in promoting the pathological intracellular 
Ca2+ leak that underlies age-dependent loss of muscle func-
tion [188]. To investigate in detail the effects of mitochon-
drial anti-oxidative capacity on age-dependent skeletal 
muscle dysfunction and Ca2+ signaling we used a genetic 
model with enhanced mitochondrial anti-oxidant activity, 
in which the human catalase gene is targeted to and over-
expressed in mitochondria. Mitochondrial overexpression 
of catalase resulted in reduced mitochondrial ROS levels, 
improved both whole organism (exercise capacity), and 
skeletal muscle (specific force) performance, and prevented 
age-related reduction in Ca2+ transients, also diminishing 
SR Ca2+ leak and age-dependent biochemical modifications 
of RyR1 [188]. 
 In the heart, aging causes several structural modifications, 
even in the absence of overt cardiovascular disease. Albeit 
contractility at rest does not appear to be affected by age, the 
ability to increase ejection fraction during exercise declines in 
elderly, and relaxation is impaired in aged individuals com-
pared to younger adults suggesting a blunted cardiac reserve 
[107]. In particular, aging results in significant biochemical 
and physiological changes in the E-C machinery.  
 The amount of Ca2+ delivered to the cytoplasm and the 
rate of Ca2+ removal are two of the major factors determining 
the rate, intensity and duration of myocyte contraction [35]. 
Since cardiac contraction largely reflects the magnitude and 
time course of increases in cytosolic Ca2+ (i.e. Ca2+ tran-
sients), processes affecting Ca2+ transients have been of in-
terest when investigating the impact of age on cardiac con-
tractile function. Several studies have focused on the effect 
of aging on contraction and Ca2+ homeostasis at the level of 
the individual ventricular myocyte.  
 Aged cardiomyocytes typically exhibit a decrease in 
their ability to augment contractions and Ca2+ transients 
following ?AR stimulation, and the rates of decay of con-
tractions and Ca2+ transients are prolonged [35, 277]. This 
may be attributed at least in part to an age-related reduced 
catecholamine sensitivity and impaired ?AR signaling 
[109, 113]. The ability of individual ventricular myocytes 
to contract declines with age. Indeed, when cardiomyocytes 
are paced at slow stimulation rates (<1 Hz), peak contrac-
tions appear similar in young adult and aged myocytes 
from rodents [278]. However at higher, more physiological 
stimulation frequencies, the extent of cell shortening is 
lower in aged mouse ventricular myocytes than in young 
adult cells. Furthermore, re-lengthening is prolonged in 
aged myocytes [278], which also produce much smaller 
increases in peak Ca2+ transients than younger cells when 
myocytes are paced at rapid rates [279]. 
 We have demonstrated in vivo that constitutive phos-
phorylation of RyR2 at Ser2808 (RyR2-S2808D mice) leads to 
a characteristic age-related cardiac dysfunction [41]. Indeed, 
serial echocardiographic measurements over the course of a 
year revealed that transgenic mice exhibited progressive, 
age-dependent cardiac dysfunction, manifested as a reduc-
tion in ejection fraction, coupled with an increase in left ven-
tricular diameter. Similarly, cardiac catheterization at 1, 2, 6, 
and 12 months of age revealed a gradual deterioration of 
myocardial contractility in RyR2-S2808D mice that was not 
evident in WT littermates [41]. We also observed significant 
decreases in the levels of PDE4D3, PP1, PP2A, and cal-
stabin2 in the RyR2 macromolecular complex by 6 to 12 
months of age, consistent with development of myocardial 
dysfunction. Furthermore, RyR2-S2808D mice displayed 
age-associated increases in both Cys-nitrosylation and oxida-
tion of cardiac RyR2, which contribute to the age-dependent 
depletion of calstabin2 from the RyR2 complex in these 
mice. Similar post-translational modifications have been 
found in patients with end-stage HF and in mice with post-
ischemic HF [41, 105].  
 More recently, we characterized the cardiac phenotype of 
calstabin2 KO mice, revealing an age-associated impaired 
cardiac function compared to WT littermates, accompanied 
by augmented cardiac fibrosis, cell death, and shorter te-
lomeres. We also demonstrated that calstabin2 deletion re-
sulted in activation of the AKT/mTOR pathway, upregula-
tion of microRNA-34, and impaired autophagy in the heart 
[35], all established hallmarks of aging [280]. 
 The role of IP3Rs in aging remains elusive, with reports 
of its involvement in the regulation of C. elegans lifespan 
[273] and other studies in mammals investigating its associa-
tion with neurodegenerative disorders, as discussed in the 
dedicated section. 
CONFLICT OF INTEREST 
 Dr. Andrew R. Marks, MD is a consultant and member of 
the board of ARMGO that is targeting RyR channels for 
therapeutic purposes. 
ACKNOWLEDGEMENTS 
 Dr. Gaetano Santulli, MD, PhD is supported by the 
American Heart Association (AHA: 13POST16810041 and 
15SDG25300007). Work presented in this article was sup-
ported by the NIH (R01-HL102040, R01-HL061503, 
R01AR060037) and Leducq Foundation. 
10    Current Molecular Pharmacology, 2015, Vol. 8, No. 2 Santulli and Marks 
REFERENCES 
[1] Marks, A. R. Intracellular calcium-release channels: regulators of 
cell life and death. Am. J. Physiol., 1997, 272, H597-605. 
[2] Rosemblit, N.; Moschella, M. C.; Ondriasa, E.; Gutstein, D. E.; 
Ondrias, K.; Marks, A. R. Intracellular calcium release channel ex-
pression during embryogenesis. Dev. Biol., 1999, 206, 163-177. 
[3] Whyte, M. K.; Hardwick, S. J.; Meagher, L. C.; Savill, J. S.; 
Haslett, C. Transient elevations of cytosolic free calcium retard 
subsequent apoptosis in neutrophils in vitro. J. Clin. Invest., 1993, 
92, 446-455. 
[4] Hong, C. Y.; Chiang, B. N.; Turner, P. Calcium ion is the key 
regulator of human sperm function. Lancet, 1984, 2, 1449-1451. 
[5] Santulli, G.; Pagano, G.; Sardu, C.; Xie, W.; Reiken, S.; D'Ascia, S. 
L.; Cannone, M.; Marziliano, N.; Trimarco, B.; Guise, T. A.; La-
campagne, A.; Marks, A. R. Calcium release channel RyR2 regu-
lates insulin release and glucose homeostasis. J. Clin. Invest., 2015, 
125, 1968-1978. 
[6] Ringer, S. A further Contribution regarding the influence of the 
different Constituents of the Blood on the Contraction of the Heart. 
J. Physiol., 1883, 4, 29-42. 
[7] Zetterstrom, R.; Arnhold, R. G. Impaired calcium-phosphate ho-
meostasis in newborn infants of diabetic mothers. Acta Paediatr., 
1958, 47, 107-112. 
[8] Jayaraman, T.; Marks, A. R. Calcineurin is downstream of the 
inositol 1,4,5-trisphosphate receptor in the apoptotic and cell 
growth pathways. J. Biol. Chem., 2000, 275, 6417-6420. 
[9] Blaustein, M. P. Physiological effects of endogenous ouabain: 
control of intracellular Ca2+ stores and cell responsiveness. Am. J. 
Physiol., 1993, 264, C1367-1387. 
[10] Chen, S.; Novick, P.; Ferro-Novick, S. ER structure and function. 
Curr. Opin. Cell Biol., 2013, 25, 428-433. 
[11] Brochet, D. X.; Yang, D.; Di Maio, A.; Lederer, W. J.; Franzini-
Armstrong, C.; Cheng, H. Ca2+ blinks: rapid nanoscopic store cal-
cium signaling. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 3099-
3104. 
[12] Flucher, B. E.; Andrews, S. B.; Fleischer, S.; Marks, A. R.; 
Caswell, A.; Powell, J. A. Triad formation: organization and func-
tion of the sarcoplasmic reticulum calcium release channel and tri-
adin in normal and dysgenic muscle in vitro. J. Cell Biol., 1993, 
123, 1161-1174. 
[13] Park, S. H.; Zhu, P. P.; Parker, R. L.; Blackstone, C. Hereditary 
spastic paraplegia proteins REEP1, spastin, and atlastin-1 coordi-
nate microtubule interactions with the tubular ER network. J. Clin. 
Invest., 2010, 120, 1097-1110. 
[14] Xu, C.; Bailly-Maitre, B.; Reed, J. C. Endoplasmic reticulum 
stress: cell life and death decisions. J. Clin. Invest., 2005, 115, 
2656-2664. 
[15] Lackner, L. L.; Ping, H.; Graef, M.; Murley, A.; Nunnari, J. Endo-
plasmic reticulum-associated mitochondria-cortex tether functions 
in the distribution and inheritance of mitochondria. Proc. Natl. 
Acad. Sci. U. S. A., 2013, 110, E458-467. 
[16] Go, L. O.; Moschella, M. C.; Watras, J.; Handa, K. K.; Fyfe, B. S.; 
Marks, A. R. Differential regulation of two types of intracellular 
calcium release channels during end-stage heart failure. J. Clin. In-
vest., 1995, 95, 888-894. 
[17] Zalk, R.; Clarke, O. B.; des Georges, A.; Grassucci, R. A.; Reiken, 
S.; Mancia, F.; Hendrickson, W. A.; Frank, J.; Marks, A. R. Struc-
ture of a mammalian ryanodine receptor. Nature, 2015, 517, 44-49. 
[18] Cai, X.; Clapham, D. E. Ancestral Ca2+ signaling machinery in 
early animal and fungal evolution. Mol. Biol. Evol., 2012, 29, 91-
100. 
[19] Liu, Y.; Li, C.; Gao, J.; Wang, W.; Huang, L.; Guo, X.; Li, B.; 
Wang, J. Comparative characterization of two intracellular Ca(2+)-
release channels from the red flour beetle, Tribolium castaneum. 
Sci. Rep., 2014, 4, 6702. 
[20] Harnick, D. J.; Jayaraman, T.; Ma, Y.; Mulieri, P.; Go, L. O.; 
Marks, A. R. The human type 1 inositol 1,4,5-trisphosphate recep-
tor from T lymphocytes. Structure, localization, and tyrosine phos-
phorylation. J. Biol. Chem., 1995, 270, 2833-2840. 
[21] Marks, A. R.; Tempst, P.; Hwang, K. S.; Taubman, M. B.; Inui, M.; 
Chadwick, C.; Fleischer, S.; Nadal-Ginard, B. Molecular cloning 
and characterization of the ryanodine receptor/junctional channel 
complex cDNA from skeletal muscle sarcoplasmic reticulum. Proc. 
Natl. Acad. Sci. U. S. A., 1989, 86, 8683-8687. 
[22] Brillantes, A. M.; Bezprozvannaya, S.; Marks, A. R. Developmen-
tal and tissue-specific regulation of rabbit skeletal and cardiac mus-
cle calcium channels involved in excitation-contraction coupling. 
Circ. Res., 1994, 75, 503-510. 
[23] Marks, A. R.; Fleischer, S.; Tempst, P. Surface topography analysis 
of the ryanodine receptor/junctional channel complex based on pro-
teolysis sensitivity mapping. J. Biol. Chem., 1990, 265, 13143-
13149. 
[24] Otsu, K.; Willard, H. F.; Khanna, V. K.; Zorzato, F.; Green, N. M.; 
MacLennan, D. H. Molecular cloning of cDNA encoding the Ca2+ 
release channel (ryanodine receptor) of rabbit cardiac muscle sar-
coplasmic reticulum. J. Biol. Chem., 1990, 265, 13472-13483. 
[25] Awad, S. S.; Lamb, H. K.; Morgan, J. M.; Dunlop, W.; Gillespie, J. 
I. Differential expression of ryanodine receptor RyR2 mRNA in the 
non-pregnant and pregnant human myometrium. Biochem. J., 1997, 
322 (Pt 3), 777-783. 
[26] Nakashima, Y.; Nishimura, S.; Maeda, A.; Barsoumian, E. L.; 
Hakamata, Y.; Nakai, J.; Allen, P. D.; Imoto, K.; Kita, T. Molecu-
lar cloning and characterization of a human brain ryanodine recep-
tor. FEBS Lett., 1997, 417, 157-162. 
[27] Zhang, L.; Liu, Y.; Song, F.; Zheng, H.; Hu, L.; Lu, H.; Liu, P.; 
Hao, X.; Zhang, W.; Chen, K. Functional SNP in the microRNA-
367 binding site in the 3'UTR of the calcium channel ryanodine re-
ceptor gene 3 (RYR3) affects breast cancer risk and calcification. 
Proc. Natl. Acad. Sci. U. S. A., 2011, 108, 13653-13658. 
[28] Rogers, E. F.; Koniuszy, F. R.; et al. Plant insecticides; ryanodine, 
a new alkaloid from Ryania speciosa Vahl. J. Am. Chem. Soc., 
1948, 70, 3086-3088. 
[29] Fairhurst, A. S.; Hasselbach, W. Calcium efflux from a heavy 
sarcotubular fraction. Effects of ryanodine, caffeine and magne-
sium. Eur. J. Biochem., 1970, 13, 504-509. 
[30] Copello, J. A.; Barg, S.; Onoue, H.; Fleischer, S. Heterogeneity of 
Ca2+ gating of skeletal muscle and cardiac ryanodine receptors. 
Biophys. J., 1997, 73, 141-156. 
[31] Laver, D. R.; Roden, L. D.; Ahern, G. P.; Eager, K. R.; Junankar, 
P. R.; Dulhunty, A. F. Cytoplasmic Ca2+ inhibits the ryanodine re-
ceptor from cardiac muscle. J. Membr. Biol., 1995, 147, 7-22. 
[32] Marks, A. R.; Marx, S. O.; Reiken, S. Regulation of ryanodine 
receptors via macromolecular complexes: a novel role for 
leucine/isoleucine zippers. Trends Cardiovasc. Med., 2002, 12, 
166-170. 
[33] Timerman, A. P.; Ogunbumni, E.; Freund, E.; Wiederrecht, G.; 
Marks, A. R.; Fleischer, S. The calcium release channel of sarco-
plasmic reticulum is modulated by FK-506-binding protein. Disso-
ciation and reconstitution of FKBP-12 to the calcium release chan-
nel of skeletal muscle sarcoplasmic reticulum. J. Biol. Chem., 
1993, 268, 22992-22999. 
[34] Xin, H. B.; Timerman, A. P.; Onoue, H.; Wiederrecht, G. J.; 
Fleischer, S. Affinity purification of the ryanodine receptor/calcium 
release channel from fast twitch skeletal muscle based on its tight 
association with FKBP12. Biochem. Biophys. Res. Commun., 1995, 
214, 263-270. 
[35] Yuan, Q.; Chen, Z.; Santulli, G.; Gu, L.; Yang, Z. G.; Yuan, Z. Q.; 
Zhao, Y. T.; Xin, H. B.; Deng, K. Y.; Wang, S. Q.; Ji, G. Func-
tional Role of Calstabin2 in Age-related Cardiac Alterations. Sci. 
Rep., 2014, 4, 7425. 
[36] Brillantes, A. B.; Ondrias, K.; Scott, A.; Kobrinsky, E.; Ondria-
sova, E.; Moschella, M. C.; Jayaraman, T.; Landers, M.; Ehrlich, B. 
E.; Marks, A. R. Stabilization of calcium release channel (ryano-
dine receptor) function by FK506-binding protein. Cell, 1994, 77, 
513-523. 
[37] Huang, F.; Shan, J.; Reiken, S.; Wehrens, X. H.; Marks, A. R. 
Analysis of calstabin2 (FKBP12.6)-ryanodine receptor interactions: 
rescue of heart failure by calstabin2 in mice. Proc. Natl. Acad. Sci. 
U. S. A., 2006, 103, 3456-3461. 
[38] Marks, A. R. A guide for the perplexed: towards an understanding 
of the molecular basis of heart failure. Circulation, 2003, 107, 
1456-1459. 
[39] Marx, S. O.; Reiken, S.; Hisamatsu, Y.; Gaburjakova, M.; Gabur-
jakova, J.; Yang, Y. M.; Rosemblit, N.; Marks, A. R. Phosphoryla-
tion-dependent regulation of ryanodine receptors: a novel role for 
leucine/isoleucine zippers. J. Cell Biol., 2001, 153, 699-708. 
[40] Reiken, S.; Lacampagne, A.; Zhou, H.; Kherani, A.; Lehnart, S. E.; 
Ward, C.; Huang, F.; Gaburjakova, M.; Gaburjakova, J.; Rosem-
blit, N.; Warren, M. S.; He, K. L.; Yi, G. H.; Wang, J.; Burkhoff, 
D.; Vassort, G.; Marks, A. R. PKA phosphorylation activates the 
IP3Rs and RyRs in Human Pathophysiology Current Molecular Pharmacology, 2015, Vol. 8, No. 2    11 
calcium release channel (ryanodine receptor) in skeletal muscle: 
defective regulation in heart failure. J. Cell Biol., 2003, 160, 919-
928. 
[41] Shan, J.; Betzenhauser, M. J.; Kushnir, A.; Reiken, S.; Meli, A. C.; 
Wronska, A.; Dura, M.; Chen, B. X.; Marks, A. R. Role of chronic 
ryanodine receptor phosphorylation in heart failure and beta-
adrenergic receptor blockade in mice. J. Clin. Invest., 2010, 120, 
4375-4387. 
[42] Kushnir, A.; Shan, J.; Betzenhauser, M. J.; Reiken, S.; Marks, A. 
R. Role of CaMKIIdelta phosphorylation of the cardiac ryanodine 
receptor in the force frequency relationship and heart failure. Proc. 
Natl. Acad. Sci. U. S. A., 2010, 107, 10274-10279. 
[43] Lehnart, S. E.; Wehrens, X. H.; Reiken, S.; Warrier, S.; Belevych, 
A. E.; Harvey, R. D.; Richter, W.; Jin, S. L.; Conti, M.; Marks, A. 
R. Phosphodiesterase 4D deficiency in the ryanodine-receptor 
complex promotes heart failure and arrhythmias. Cell, 2005, 123, 
25-35. 
[44] Marx, S. O.; Reiken, S.; Hisamatsu, Y.; Jayaraman, T.; Burkhoff, 
D.; Rosemblit, N.; Marks, A. R. PKA phosphorylation dissociates 
FKBP12.6 from the calcium release channel (ryanodine receptor): 
defective regulation in failing hearts. Cell, 2000, 101, 365-376. 
[45] Shan, J.; Kushnir, A.; Betzenhauser, M. J.; Reiken, S.; Li, J.; 
Lehnart, S. E.; Lindegger, N.; Mongillo, M.; Mohler, P. J.; Marks, 
A. R. Phosphorylation of the ryanodine receptor mediates the car-
diac fight or flight response in mice. J. Clin. Invest., 2010, 120, 
4388-4398. 
[46] Liu, X.; Betzenhauser, M. J.; Reiken, S.; Meli, A. C.; Xie, W.; 
Chen, B. X.; Arancio, O.; Marks, A. R. Role of leaky neuronal rya-
nodine receptors in stress-induced cognitive dysfunction. Cell, 
2012, 150, 1055-1067. 
[47] Andersson, D. C.; Betzenhauser, M. J.; Reiken, S.; Meli, A. C.; 
Umanskaya, A.; Xie, W.; Shiomi, T.; Zalk, R.; Lacampagne, A.; 
Marks, A. R. Ryanodine receptor oxidation causes intracellular cal-
cium leak and muscle weakness in aging. Cell Metab., 2011, 14, 
196-207. 
[48] Tester, D. J.; Dura, M.; Carturan, E.; Reiken, S.; Wronska, A.; 
Marks, A. R.; Ackerman, M. J. A mechanism for sudden infant 
death syndrome (SIDS): stress-induced leak via ryanodine recep-
tors. Heart Rhythm, 2007, 4, 733-739. 
[49] Maki, T.; Gruver, E. J.; Davidoff, A. J.; Izzo, N.; Toupin, D.; 
Colucci, W.; Marks, A. R.; Marsh, J. D. Regulation of calcium 
channel expression in neonatal myocytes by catecholamines. J. 
Clin. Invest., 1996, 97, 656-663. 
[50] Fauconnier, J.; Thireau, J.; Reiken, S.; Cassan, C.; Richard, S.; 
Matecki, S.; Marks, A. R.; Lacampagne, A. Leaky RyR2 trigger 
ventricular arrhythmias in Duchenne muscular dystrophy. Proc. 
Natl. Acad. Sci. U. S. A., 2010, 107, 1559-1564. 
[51] Frank, K. F.; Bolck, B.; Ding, Z.; Krause, D.; Hattebuhr, N.; Malik, 
A.; Brixius, K.; Hajjar, R. J.; Schrader, J.; Schwinger, R. H. Over-
expression of sorcin enhances cardiac contractility in vivo and in vi-
tro. J. Mol. Cell. Cardiol., 2005, 38, 607-615. 
[52] Meissner, G.; Henderson, J. S. Rapid calcium release from cardiac 
sarcoplasmic reticulum vesicles is dependent on Ca2+ and is modu-
lated by Mg2+, adenine nucleotide, and calmodulin. J. Biol. Chem., 
1987, 262, 3065-3073. 
[53] Feng, W.; Tu, J.; Yang, T.; Vernon, P. S.; Allen, P. D.; Worley, P. 
F.; Pessah, I. N. Homer regulates gain of ryanodine receptor type 1 
channel complex. J. Biol. Chem., 2002, 277, 44722-44730. 
[54] Lee, H. G.; Kang, H.; Kim, D. H.; Park, W. J. Interaction of HRC 
(histidine-rich Ca(2+)-binding protein) and triadin in the lumen of 
sarcoplasmic reticulum. J. Biol. Chem., 2001, 276, 39533-39538. 
[55] Ritterhoff, J.; Volkers, M.; Seitz, A.; Spaich, K.; Gao, E.; Peppel, 
K.; Pleger, S. T.; Zimmermann, W. H.; Friedrich, O.; Fink, R. H.; 
Koch, W. J.; Katus, H. A.; Most, P. S100A1 DNA-based inotropic 
therapy protects against pro-arrhythmogenic ryanodine receptor 2 
dysfunction. Mol. Ther., 2015. 
[56] Rossi, D.; Bencini, C.; Maritati, M.; Benini, F.; Lorenzini, S.; Pier-
antozzi, E.; Scarcella, A. M.; Paolini, C.; Protasi, F.; Sorrentino, V. 
Distinct regions of triadin are required for targeting and retention at 
the junctional domain of the sarcoplasmic reticulum. Biochem. J., 
2014, 458, 407-417. 
[57] Zhang, L.; Kelley, J.; Schmeisser, G.; Kobayashi, Y. M.; Jones, L. 
R. Complex formation between junctin, triadin, calsequestrin, and 
the ryanodine receptor. Proteins of the cardiac junctional sarco-
plasmic reticulum membrane. J. Biol. Chem., 1997, 272, 23389-
23397. 
[58] Ohkura, M.; Furukawa, K.; Fujimori, H.; Kuruma, A.; Kawano, S.; 
Hiraoka, M.; Kuniyasu, A.; Nakayama, H.; Ohizumi, Y. Dual regu-
lation of the skeletal muscle ryanodine receptor by triadin and cal-
sequestrin. Biochemistry, 1998, 37, 12987-12993. 
[59] Bosanac, I.; Alattia, J. R.; Mal, T. K.; Chan, J.; Talarico, S.; Tong, 
F. K.; Tong, K. I.; Yoshikawa, F.; Furuichi, T.; Iwai, M.; Michi-
kawa, T.; Mikoshiba, K.; Ikura, M. Structure of the inositol 1,4,5-
trisphosphate receptor binding core in complex with its ligand. Na-
ture, 2002, 420, 696-700. 
[60] Furuichi, T.; Yoshikawa, S.; Miyawaki, A.; Wada, K.; Maeda, N.; 
Mikoshiba, K. Primary structure and functional expression of the 
inositol 1,4,5-trisphosphate-binding protein P400. Nature, 1989, 
342, 32-38. 
[61] Mignery, G. A.; Sudhof, T. C.; Takei, K.; De Camilli, P. Putative 
receptor for inositol 1,4,5-trisphosphate similar to ryanodine recep-
tor. Nature, 1989, 342, 192-195. 
[62] Marks, A. R.; Tempst, P.; Chadwick, C. C.; Riviere, L.; Fleischer, 
S.; Nadal-Ginard, B. Smooth muscle and brain inositol 1,4,5-
trisphosphate receptors are structurally and functionally similar. J. 
Biol. Chem., 1990, 265, 20719-20722. 
[63] Nakagawa, T.; Okano, H.; Furuichi, T.; Aruga, J.; Mikoshiba, K. 
The subtypes of the mouse inositol 1,4,5-trisphosphate receptor are 
expressed in a tissue-specific and developmentally specific manner. 
Proc. Natl. Acad. Sci. U. S. A., 1991, 88, 6244-6248. 
[64] Vermassen, E.; Parys, J. B.; Mauger, J. P. Subcellular distribution 
of the inositol 1,4,5-trisphosphate receptors: functional relevance 
and molecular determinants. Biol. Cell., 2004, 96, 3-17. 
[65] Supattapone, S.; Worley, P. F.; Baraban, J. M.; Snyder, S. H. Solu-
bilization, purification, and characterization of an inositol trisphos-
phate receptor. J. Biol. Chem., 1988, 263, 1530-1534. 
[66] Narayanan, D.; Adebiyi, A.; Jaggar, J. H. Inositol trisphosphate 
receptors in smooth muscle cells. Am. J. Physiol. Heart Circ. 
Physiol., 2012, 302, H2190-2210. 
[67] deSouza, N.; Cui, J.; Dura, M.; McDonald, T. V.; Marks, A. R. A 
function for tyrosine phosphorylation of type 1 inositol 1,4,5-
trisphosphate receptor in lymphocyte activation. J. Cell Biol., 2007, 
179, 923-934. 
[68] Klar, J.; Hisatsune, C.; Baig, S. M.; Tariq, M.; Johansson, A. C.; 
Rasool, M.; Malik, N. A.; Ameur, A.; Sugiura, K.; Feuk, L.; Miko-
shiba, K.; Dahl, N. Abolished InsP3R2 function inhibits sweat se-
cretion in both humans and mice. J. Clin. Invest., 2014, 124, 4773-
4780. 
[69] De Smedt, H.; Missiaen, L.; Parys, J. B.; Henning, R. H.; Sienaert, 
I.; Vanlingen, S.; Gijsens, A.; Himpens, B.; Casteels, R. Isoform 
diversity of the inositol trisphosphate receptor in cell types of 
mouse origin. Biochem. J., 1997, 322 (Pt 2), 575-583. 
[70] Missiaen, L.; Parys, J. B.; De Smedt, H.; Sienaert, I.; Henning, R. 
H.; Casteels, R. Opening up Ca2+ stores with InsP3. Nature, 1995, 
376, 299-300; author reply 301. 
[71] Jayaraman, T.; Ondriasova, E.; Ondrias, K.; Harnick, D. J.; Marks, 
A. R. The inositol 1,4,5-trisphosphate receptor is essential for T-
cell receptor signaling. Proc. Natl. Acad. Sci. U. S. A., 1995, 92, 
6007-6011. 
[72] Suzuki, T.; Imai, J.; Yamada, T.; Ishigaki, Y.; Kaneko, K.; Uno, 
K.; Hasegawa, Y.; Ishihara, H.; Oka, Y.; Katagiri, H. Interleukin-6 
enhances glucose-stimulated insulin secretion from pancreatic beta-
cells: potential involvement of the PLC-IP3-dependent pathway. 
Diabetes, 2011, 60, 537-547. 
[73] Jayaraman, T.; Ondrias, K.; Ondriasova, E.; Marks, A. R. Regula-
tion of the inositol 1,4,5-trisphosphate receptor by tyrosine phos-
phorylation. Science, 1996, 272, 1492-1494. 
[74] Sienaert, I.; Nadif Kasri, N.; Vanlingen, S.; Parys, J. B.; Calle-
waert, G.; Missiaen, L.; de Smedt, H. Localization and function of 
a calmodulin-apocalmodulin-binding domain in the N-terminal part 
of the type 1 inositol 1,4,5-trisphosphate receptor. Biochem. J., 
2002, 365, 269-277. 
[75] Yang, J.; McBride, S.; Mak, D. O.; Vardi, N.; Palczewski, K.; 
Haeseleer, F.; Foskett, J. K. Identification of a family of calcium 
sensors as protein ligands of inositol trisphosphate receptor Ca(2+) 
release channels. Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 7711-
7716. 
[76] Hirota, J.; Ando, H.; Hamada, K.; Mikoshiba, K. Carbonic anhy-
drase-related protein is a novel binding protein for inositol 1,4,5-
trisphosphate receptor type 1. Biochem. J., 2003, 372, 435-441. 
[77] Joseph, S. K.; Samanta, S. Detergent solubility of the inositol 
trisphosphate receptor in rat brain membranes. Evidence for asso-
12    Current Molecular Pharmacology, 2015, Vol. 8, No. 2 Santulli and Marks 
ciation of the receptor with ankyrin. J. Biol. Chem., 1993, 268, 
6477-6486. 
[78] Tu, J. C.; Xiao, B.; Yuan, J. P.; Lanahan, A. A.; Leoffert, K.; Li, 
M.; Linden, D. J.; Worley, P. F. Homer binds a novel proline-rich 
motif and links group 1 metabotropic glutamate receptors with IP3 
receptors. Neuron, 1998, 21, 717-726. 
[79] Choe, C. U.; Ehrlich, B. E. The inositol 1,4,5-trisphosphate recep-
tor (IP3R) and its regulators: sometimes good and sometimes bad 
teamwork. Sci. STKE, 2006, 2006, re15. 
[80] Rong, Y. P.; Aromolaran, A. S.; Bultynck, G.; Zhong, F.; Li, X.; 
McColl, K.; Matsuyama, S.; Herlitze, S.; Roderick, H. L.; Boot-
man, M. D.; Mignery, G. A.; Parys, J. B.; De Smedt, H.; Distel-
horst, C. W. Targeting Bcl-2-IP3 receptor interaction to reverse 
Bcl-2's inhibition of apoptotic calcium signals. Mol. Cell, 2008, 31, 
255-265. 
[81] Akl, H.; Monaco, G.; La Rovere, R.; Welkenhuyzen, K.; Kiviluoto, 
S.; Vervliet, T.; Molgo, J.; Distelhorst, C. W.; Missiaen, L.; Miko-
shiba, K.; Parys, J. B.; De Smedt, H.; Bultynck, G. IP3R2 levels 
dictate the apoptotic sensitivity of diffuse large B-cell lymphoma 
cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-
2. Cell Death Dis., 2013, 4, e632. 
[82] Vervliet, T.; Decrock, E.; Molgo, J.; Sorrentino, V.; Missiaen, L.; 
Leybaert, L.; De Smedt, H.; Kasri, N. N.; Parys, J. B.; Bultynck, G. 
Bcl-2 binds to and inhibits ryanodine receptors. J. Cell Sci., 2014, 
127, 2782-2792. 
[83] Ando, H.; Mizutani, A.; Kiefer, H.; Tsuzurugi, D.; Michikawa, T.; 
Mikoshiba, K. IRBIT suppresses IP3 receptor activity by compet-
ing with IP3 for the common binding site on the IP3 receptor. Mol. 
Cell, 2006, 22, 795-806. 
[84] Hamada, K.; Miyata, T.; Mayanagi, K.; Hirota, J.; Mikoshiba, K. 
Two-state conformational changes in inositol 1,4,5-trisphosphate 
receptor regulated by calcium. J. Biol. Chem., 2002, 277, 21115-
21118. 
[85] Ferris, C. D.; Huganir, R. L.; Bredt, D. S.; Cameron, A. M.; Sny-
der, S. H. Inositol trisphosphate receptor: phosphorylation by pro-
tein kinase C and calcium calmodulin-dependent protein kinases in 
reconstituted lipid vesicles. Proc. Natl. Acad. Sci. U. S. A., 1991, 
88, 2232-2235. 
[86] DeSouza, N.; Reiken, S.; Ondrias, K.; Yang, Y. M.; Matkovich, S.; 
Marks, A. R. Protein kinase A and two phosphatases are compo-
nents of the inositol 1,4,5-trisphosphate receptor macromolecular 
signaling complex. J. Biol. Chem., 2002, 277, 39397-39400. 
[87] Cameron, A. M.; Steiner, J. P.; Sabatini, D. M.; Kaplin, A. I.; 
Walensky, L. D.; Snyder, S. H. Immunophilin FK506 binding pro-
tein associated with inositol 1,4,5-trisphosphate receptor modulates 
calcium flux. Proc. Natl. Acad. Sci. U. S. A., 1995, 92, 1784-1788. 
[88] Bultynck, G.; De Smet, P.; Rossi, D.; Callewaert, G.; Missiaen, L.; 
Sorrentino, V.; De Smedt, H.; Parys, J. B. Characterization and 
mapping of the 12 kDa FK506-binding protein (FKBP12)-binding 
site on different isoforms of the ryanodine receptor and of the 
inositol 1,4,5-trisphosphate receptor. Biochem. J., 2001, 354, 413-
422. 
[89] Bultynck, G.; Rossi, D.; Callewaert, G.; Missiaen, L.; Sorrentino, 
V.; Parys, J. B.; De Smedt, H. The conserved sites for the FK506-
binding proteins in ryanodine receptors and inositol 1,4,5-
trisphosphate receptors are structurally and functionally different. 
J. Biol. Chem., 2001, 276, 47715-47724. 
[90] Reuter, H.; Beeler, G. W., Jr. Calcium current and activation of 
contraction in ventricular myocardial fibers. Science, 1969, 163, 
399-401. 
[91] Trautwein, W.; Kassebaum, D. G. On the mechanism of spontane-
ous impulse generation in the pacemaker of the heart. J. Gen. 
Physiol., 1961, 45, 317-330. 
[92] Reuter, H. The dependence of slow inward current in Purkinje 
fibres on the extracellular calcium-concentration. J. Physiol., 1967, 
192, 479-492. 
[93] Galvani, L. De viribus electricitatis in motu musculari commen-
tarius. De Bononiensi Scientiarum et Artium Instituto atque Aca-
demia Commentarii, 1791, 7, 363-418. 
[94] Mines, G. R. On functional analysis by the action of electrolytes. J. 
Physiol., 1913, 46, 188-235. 
[95] Winegrad, S.; Shanes, A. M. Calcium flux and contractility in 
guinea pig atria. J. Gen. Physiol., 1962, 45, 371-394. 
[96] Fabiato, A.; Fabiato, F. Calcium and cardiac excitation-contraction 
coupling. Annu. Rev. Physiol., 1979, 41, 473-484. 
[97] Santulli, G.; Wronska, A.; Uryu, K.; Diacovo, T. G.; Gao, M.; 
Marx, S. O.; Kitajewski, J.; Chilton, J. M.; Akat, K. M.; Tuschl, T.; 
Marks, A. R.; Totary-Jain, H. A selective microRNA-based strat-
egy inhibits restenosis while preserving endothelial function. J. 
Clin. Invest., 2014, 124, 4102-4114. 
[98] Santulli, G. Epidemiology of cardiovascular disease in the 21st 
century: Updated numbers and updated facts. Journal of Cardio-
vascular Disease - JCvD, 2013, 1, 1-2. 
[99] Wronska, A.; Kurkowska-Jastrzebska, I.; Santulli, G. Application 
of microRNAs in diagnosis and treatment of cardiovascular dis-
ease. Acta Physiol., 2015, 213, 60-83. 
[100] Santulli, G. Coronary heart disease risk factors and mortality. 
JAMA, 2012, 307, 1137. 
[101] D'Ascia, S. L.; D'Ascia, C.; Marino, V.; Lombardi, A.; Santulli, R.; 
Chiariello, M.; Santulli, G. Cardiac resynchronisation therapy re-
sponse predicts occurrence of atrial fibrillation in non-ischaemic di-
lated cardiomyopathy. Int. J. Clin. Pract., 2011, 65, 1149-1155. 
[102] Santulli, G.; Campanile, A.; Spinelli, L.; Assante di Panzillo, E.; 
Ciccarelli, M.; Trimarco, B.; Iaccarino, G. G protein-coupled re-
ceptor kinase 2 in patients with acute myocardial infarction. Am. J. 
Cardiol., 2011, 107, 1125-1130. 
[103] Pieske, B.; Maier, L. S.; Schmidt-Schweda, S. Sarcoplasmic reticu-
lum Ca2+ load in human heart failure. Basic Res. Cardiol., 2002, 97 
Suppl 1, I63-71. 
[104] Reiken, S.; Gaburjakova, M.; Guatimosim, S.; Gomez, A. M.; 
D'Armiento, J.; Burkhoff, D.; Wang, J.; Vassort, G.; Lederer, W. J.; 
Marks, A. R. Protein kinase A phosphorylation of the cardiac cal-
cium release channel (ryanodine receptor) in normal and failing 
hearts. Role of phosphatases and response to isoproterenol. J. Biol. 
Chem., 2003, 278, 444-453. 
[105] Santulli, G.; Xie, W.; Reiken, S. R.; Marks, A. R. Mitochondrial 
calcium overload is a key determinant in heart failure. Proc. Natl. 
Acad. Sci. U. S. A., 2015, In press. 
[106] Santulli, G. The Adrenergic System in Cardiovascular Metabolism 
and Aging. In: The Cardiovascular Adrenergic System (Editor: 
Lymperopoulos, A.) 2015, 97-118. 
[107] Santulli, G.; Ciccarelli, M.; Trimarco, B.; Iaccarino, G. Physical 
activity ameliorates cardiovascular health in elderly subjects: the 
functional role of the beta adrenergic system. Front. Physiol., 2013, 
4, 209. 
[108] Lymperopoulos, A.; Rengo, G.; Koch, W. J. Adrenergic nervous 
system in heart failure: pathophysiology and therapy. Circ. Res., 
2013, 113, 739-753. 
[109] Santulli, G.; Iaccarino, G. Pinpointing beta adrenergic receptor in 
ageing pathophysiology: victim or executioner? Evidence from 
crime scenes. Immun. Ageing, 2013, 10, 10. 
[110] Perino, A.; Ghigo, A.; Ferrero, E.; Morello, F.; Santulli, G.; Baillie, 
G. S.; Damilano, F.; Dunlop, A. J.; Pawson, C.; Walser, R.; Levi, 
R.; Altruda, F.; Silengo, L.; Langeberg, L. K.; Neubauer, G.; Hey-
mans, S.; Lembo, G.; Wymann, M. P.; Wetzker, R.; Houslay, M. 
D.; Iaccarino, G.; Scott, J. D.; Hirsch, E. Integrating cardiac PIP3 
and cAMP signaling through a PKA anchoring function of 
p110gamma. Mol. Cell, 2011, 42, 84-95. 
[111] Santulli, G. Sympathetic nervous system signaling in heart failure 
and cardiac aging. In: Pathophysiology and Pharmacotherapy of 
Cardiovascular Disease (Editors: Jagadeesh G, Balakumar P, 
Khin M) 2015, 83-105. 
[112] Santulli, G. Beta-blockers in diabetic patients with heart failure. 
JAMA Intern Med., 2015, 175, 657. 
[113] Santulli, G.; Trimarco, B.; Iaccarino, G. G-protein-coupled receptor 
kinase 2 and hypertension: molecular insights and pathophysiologi-
cal mechanisms. High Blood Press. Cardiovasc. Prev., 2013, 20, 5-
12. 
[114] Lowes, B. D.; Gilbert, E. M.; Abraham, W. T.; Minobe, W. A.; 
Larrabee, P.; Ferguson, D.; Wolfel, E. E.; Lindenfeld, J.; 
Tsvetkova, T.; Robertson, A. D.; Quaife, R. A.; Bristow, M. R. 
Myocardial gene expression in dilated cardiomyopathy treated with 
beta-blocking agents. N. Engl. J. Med., 2002, 346, 1357-1365. 
[115] Reiken, S.; Gaburjakova, M.; Gaburjakova, J.; He Kl, K. L.; Prieto, 
A.; Becker, E.; Yi Gh, G. H.; Wang, J.; Burkhoff, D.; Marks, A. R. 
beta-adrenergic receptor blockers restore cardiac calcium release 
channel (ryanodine receptor) structure and function in heart failure. 
Circulation, 2001, 104, 2843-2848. 
[116] Reiken, S.; Wehrens, X. H.; Vest, J. A.; Barbone, A.; Klotz, S.; 
Mancini, D.; Burkhoff, D.; Marks, A. R. Beta-blockers restore cal-
cium release channel function and improve cardiac muscle per-
IP3Rs and RyRs in Human Pathophysiology Current Molecular Pharmacology, 2015, Vol. 8, No. 2    13 
formance in human heart failure. Circulation, 2003, 107, 2459-
2466. 
[117] Fischer, T. H.; Herting, J.; Tirilomis, T.; Renner, A.; Neef, S.; 
Toischer, K.; Ellenberger, D.; Forster, A.; Schmitto, J. D.; Gum-
mert, J.; Schondube, F. A.; Hasenfuss, G.; Maier, L. S.; Sossalla, S. 
Ca2+ /calmodulin-dependent protein kinase II and protein kinase A 
differentially regulate sarcoplasmic reticulum Ca2+ leak in human 
cardiac pathology. Circulation, 2013, 128, 970-981. 
[118] Bowditch, H. Über die Eigentümlichkeiten der Reizbarkeit, welche 
die Muskelfasern des Herzens zeigen. Berichte über die Verhand-
lungen der Königlich Sächsischen Gesellschaft zu Leipzig; Mathe-
matisch-Physische Classe, 1871, 652–689. 
[119] Ling, H.; Zhang, T.; Pereira, L.; Means, C. K.; Cheng, H.; Gu, Y.; 
Dalton, N. D.; Peterson, K. L.; Chen, J.; Bers, D.; Brown, J. H. Re-
quirement for Ca2+ /calmodulin-dependent kinase II in the transi-
tion from pressure overload-induced cardiac hypertrophy to heart 
failure in mice. J. Clin. Invest., 2009, 119, 1230-1240. 
[120] He, B. J.; Joiner, M. L.; Singh, M. V.; Luczak, E. D.; Swamina-
than, P. D.; Koval, O. M.; Kutschke, W.; Allamargot, C.; Yang, J.; 
Guan, X.; Zimmerman, K.; Grumbach, I. M.; Weiss, R. M.; Spitz, 
D. R.; Sigmund, C. D.; Blankesteijn, W. M.; Heymans, S.; Mohler, 
P. J.; Anderson, M. E. Oxidation of CaMKII determines the car-
diotoxic effects of aldosterone. Nat. Med., 2011, 17, 1610-1618. 
[121] Ho, H. T.; Liu, B.; Snyder, J. S.; Lou, Q.; Brundage, E. A.; Velez-
Cortes, F.; Wang, H.; Ziolo, M. T.; Anderson, M. E.; Sen, C. K.; 
Wehrens, X. H.; Fedorov, V. V.; Biesiadecki, B. J.; Hund, T. J.; 
Gyorke, S. Ryanodine receptor phosphorylation by oxidized CaM-
KII contributes to the cardiotoxic effects of cardiac glycosides. 
Cardiovasc. Res., 2014, 101, 165-174. 
[122] Song, L.; Alcalai, R.; Arad, M.; Wolf, C. M.; Toka, O.; Conner, D. 
A.; Berul, C. I.; Eldar, M.; Seidman, C. E.; Seidman, J. G. Calse-
questrin 2 (CASQ2) mutations increase expression of calreticulin 
and ryanodine receptors, causing catecholaminergic polymorphic 
ventricular tachycardia. J. Clin. Invest., 2007, 117, 1814-1823. 
[123] Xie, W.; Santulli, G.; Reiken, S.; Yuan, Q.; Osborne, B.; Chen, B.; 
Marks, A. R. Mitochondrial oxidative stress promotes atrial fibril-
lation. Sci. Rep., 2015, In press. 
[124] Shan, J.; Xie, W.; Betzenhauser, M.; Reiken, S.; Chen, B. X.; 
Wronska, A.; Marks, A. R. Calcium leak through ryanodine recep-
tors leads to atrial fibrillation in 3 mouse models of catechola-
minergic polymorphic ventricular tachycardia. Circ. Res., 2012, 
111, 708-717. 
[125] Xie, W.; Santulli, G.; Guo, X.; Gao, M.; Chen, B. X.; Marks, A. R. 
Imaging atrial arrhythmic intracellular calcium in intact heart. J. 
Mol. Cell. Cardiol., 2013, 64, 120-123. 
[126] Cheng, Y.; Zhan, Q.; Zhao, J.; Xiao, J. Stabilizing ryanodine recep-
tor type 2: a novel strategy for the treatment of atrial fibrillation. 
Med. Sci. Monit., 2010, 16, HY23-26. 
[127] Vinet, L.; Pezet, M.; Bito, V.; Briec, F.; Biesmans, L.; Rouet-
Benzineb, P.; Gellen, B.; Previlon, M.; Chimenti, S.; Vilaine, J. P.; 
Charpentier, F.; Sipido, K. R.; Mercadier, J. J. Cardiac FKBP12.6 
overexpression protects against triggered ventricular tachycardia in 
pressure overloaded mouse hearts. Basic Res. Cardiol., 2012, 107, 
246. 
[128] Marks, A. R.; Priori, S.; Memmi, M.; Kontula, K.; Laitinen, P. J. 
Involvement of the cardiac ryanodine receptor/calcium release 
channel in catecholaminergic polymorphic ventricular tachycardia. 
J. Cell. Physiol., 2002, 190, 1-6. 
[129] Rampazzo, A.; Nava, A.; Erne, P.; Eberhard, M.; Vian, E.; Slomp, 
P.; Tiso, N.; Thiene, G.; Danieli, G. A. A new locus for arrhyth-
mogenic right ventricular cardiomyopathy (ARVD2) maps to 
chromosome 1q42-q43. Hum. Mol. Genet., 1995, 4, 2151-2154. 
[130] Campbell, M. J.; Czosek, R. J.; Hinton, R. B.; Miller, E. M. Exon 3 
deletion of ryanodine receptor causes left ventricular noncompac-
tion, worsening catecholaminergic polymorphic ventricular tachy-
cardia, and sudden cardiac arrest. Am. J. Med. Genet. A, 2015. 
[131] Wehrens, X. H.; Lehnart, S. E.; Huang, F.; Vest, J. A.; Reiken, S. 
R.; Mohler, P. J.; Sun, J.; Guatimosim, S.; Song, L. S.; Rosemblit, 
N.; D'Armiento, J. M.; Napolitano, C.; Memmi, M.; Priori, S. G.; 
Lederer, W. J.; Marks, A. R. FKBP12.6 deficiency and defective 
calcium release channel (ryanodine receptor) function linked to ex-
ercise-induced sudden cardiac death. Cell, 2003, 113, 829-840. 
[132] Mallat, Z.; Tedgui, A.; Fontaliran, F.; Frank, R.; Durigon, M.; 
Fontaine, G. Evidence of apoptosis in arrhythmogenic right ven-
tricular dysplasia. N. Engl. J. Med., 1996, 335, 1190-1196. 
[133] Santulli, G. Classification of syncope-producing cardiac arrhyth-
mias. In: Comas and syncope: causes, prevention and treatment - 
Nova Science Publisher, New York, NY; 2012, 167-177. 
[134] Tiso, N.; Stephan, D. A.; Nava, A.; Bagattin, A.; Devaney, J. M.; 
Stanchi, F.; Larderet, G.; Brahmbhatt, B.; Brown, K.; Bauce, B.; 
Muriago, M.; Basso, C.; Thiene, G.; Danieli, G. A.; Rampazzo, A. 
Identification of mutations in the cardiac ryanodine receptor gene 
in families affected with arrhythmogenic right ventricular cardio-
myopathy type 2 (ARVD2). Hum. Mol. Genet., 2001, 10, 189-194. 
[135] Asimaki, A.; Tandri, H.; Huang, H.; Halushka, M. K.; Gautam, S.; 
Basso, C.; Thiene, G.; Tsatsopoulou, A.; Protonotarios, N.; 
McKenna, W. J.; Calkins, H.; Saffitz, J. E. A new diagnostic test 
for arrhythmogenic right ventricular cardiomyopathy. N. Engl. J. 
Med., 2009, 360, 1075-1084. 
[136] Sumitomo, N.; Harada, K.; Nagashima, M.; Yasuda, T.; Nakamura, 
Y.; Aragaki, Y.; Saito, A.; Kurosaki, K.; Jouo, K.; Koujiro, M.; 
Konishi, S.; Matsuoka, S.; Oono, T.; Hayakawa, S.; Miura, M.; 
Ushinohama, H.; Shibata, T.; Niimura, I. Catecholaminergic poly-
morphic ventricular tachycardia: electrocardiographic characteris-
tics and optimal therapeutic strategies to prevent sudden death. 
Heart, 2003, 89, 66-70. 
[137] Lehnart, S. E.; Terrenoire, C.; Reiken, S.; Wehrens, X. H.; Song, L. 
S.; Tillman, E. J.; Mancarella, S.; Coromilas, J.; Lederer, W. J.; 
Kass, R. S.; Marks, A. R. Stabilization of cardiac ryanodine recep-
tor prevents intracellular calcium leak and arrhythmias. Proc. Natl. 
Acad. Sci. U. S. A., 2006, 103, 7906-7910. 
[138] Chelu, M. G.; Sarma, S.; Sood, S.; Wang, S.; van Oort, R. J.; Ska-
pura, D. G.; Li, N.; Santonastasi, M.; Muller, F. U.; Schmitz, W.; 
Schotten, U.; Anderson, M. E.; Valderrabano, M.; Dobrev, D.; We-
hrens, X. H. Calmodulin kinase II-mediated sarcoplasmic reticulum 
Ca2+ leak promotes atrial fibrillation in mice. J. Clin. Invest., 2009, 
119, 1940-1951. 
[139] Cooley, N.; Ouyang, K.; McMullen, J. R.; Kiriazis, H.; Sheikh, F.; 
Wu, W.; Mu, Y.; Du, X. J.; Chen, J.; Woodcock, E. A. No contri-
bution of IP3-R(2) to disease phenotype in models of dilated car-
diomyopathy or pressure overload hypertrophy. Circ. Heart Fail., 
2013, 6, 318-325. 
[140] Moschella, M. C.; Marks, A. R. Inositol 1,4,5-trisphosphate recep-
tor expression in cardiac myocytes. J. Cell Biol., 1993, 120, 1137-
1146. 
[141] Zima, A. V.; Blatter, L. A. Inositol-1,4,5-trisphosphate-dependent 
Ca(2+) signalling in cat atrial excitation-contraction coupling and 
arrhythmias. J. Physiol., 2004, 555, 607-615. 
[142] Taylor, C. W.; Tovey, S. C. IP(3) receptors: toward understanding 
their activation. Cold Spring Harb. Perspect. Biol., 2010, 2, 
a004010. 
[143] Kentish, J. C.; Barsotti, R. J.; Lea, T. J.; Mulligan, I. P.; Patel, J. R.; 
Ferenczi, M. A. Calcium release from cardiac sarcoplasmic reticu-
lum induced by photorelease of calcium or Ins(1,4,5)P3. Am. J. 
Physiol., 1990, 258, H610-615. 
[144] Hansen, C. A.; Joseph, S. K.; Robishaw, J. D. Ins 1,4,5-P3 and Ca2+ 
signaling in quiescent neonatal cardiac myocytes. Biochim. Bio-
phys. Acta, 1994, 1224, 517-526. 
[145] Lipp, P.; Laine, M.; Tovey, S. C.; Burrell, K. M.; Berridge, M. J.; 
Li, W.; Bootman, M. D. Functional InsP3 receptors that may 
modulate excitation-contraction coupling in the heart. Curr. Biol., 
2000, 10, 939-942. 
[146] Gorza, L.; Schiaffino, S.; Volpe, P. Inositol 1,4,5-trisphosphate 
receptor in heart: evidence for its concentration in Purkinje myo-
cytes of the conduction system. J. Cell Biol., 1993, 121, 345-353. 
[147] Verma, A.; Hirsch, D. J.; Snyder, S. H. Calcium pools mobilized 
by calcium or inositol 1,4,5-trisphosphate are differentially local-
ized in rat heart and brain. Mol. Biol. Cell, 1992, 3, 621-631. 
[148] Wu, X.; Zhang, T.; Bossuyt, J.; Li, X.; McKinsey, T. A.; Dedman, 
J. R.; Olson, E. N.; Chen, J.; Brown, J. H.; Bers, D. M. Local 
InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte ex-
citation-transcription coupling. J. Clin. Invest., 2006, 116, 675-682. 
[149] Bootman, M. D.; Collins, T. J.; Mackenzie, L.; Roderick, H. L.; 
Berridge, M. J.; Peppiatt, C. M. 2-aminoethoxydiphenyl borate (2-
APB) is a reliable blocker of store-operated Ca2+ entry but an in-
consistent inhibitor of InsP3-induced Ca2+ release. FASEB J., 2002, 
16, 1145-1150. 
[150] Harzheim, D.; Talasila, A.; Movassagh, M.; Foo, R. S.; Figg, N.; 
Bootman, M. D.; Roderick, H. L. Elevated InsP3R expression un-
derlies enhanced calcium fluxes and spontaneous extra-systolic 
14    Current Molecular Pharmacology, 2015, Vol. 8, No. 2 Santulli and Marks 
calcium release events in hypertrophic cardiac myocytes. Channels, 
2010, 4, 67-71. 
[151] Liang, X.; Xie, H.; Zhu, P. H.; Hu, J.; Zhao, Q.; Wang, C. S.; 
Yang, C. Enhanced activity of inositol-1,4,5-trisphosphate recep-
tors in atrial myocytes of atrial fibrillation patients. Cardiology, 
2009, 114, 180-191. 
[152] Yamda, J.; Ohkusa, T.; Nao, T.; Ueyama, T.; Yano, M.; Kobayashi, 
S.; Hamano, K.; Esato, K.; Matsuzaki, M. Up-regulation of inositol 
1,4,5 trisphosphate receptor expression in atrial tissue in patients 
with chronic atrial fibrillation. J. Am. Coll. Cardiol., 2001, 37, 
1111-1119. 
[153] Santulli, G.; Iaccarino, G.; De Luca, N.; Trimarco, B.; Condorelli, 
G. Atrial fibrillation and microRNAs. Front. Physiol., 2014, 5, 15. 
[154] Santulli, G.; D'Ascia S, L.; D'Ascia, C. Development of atrial fib-
rillation in recipients of cardiac resynchronization therapy: the role 
of atrial reverse remodelling. Can. J. Cardiol., 2012, 28, 245 e217. 
[155] Xiao, J.; Liang, D.; Zhao, H.; Liu, Y.; Zhang, H.; Lu, X.; Liu, Y.; 
Li, J.; Peng, L.; Chen, Y. H. 2-Aminoethoxydiphenyl borate, a 
inositol 1,4,5-triphosphate receptor inhibitor, prevents atrial fibril-
lation. Exp. Biol. Med. (Maywood), 2010, 235, 862-868. 
[156] Mouton, R.; Huisamen, B.; Lochner, A. Increased myocardial 
inositol trisphosphate levels during alpha 1-adrenergic stimulation 
and reperfusion of ischaemic rat heart. J. Mol. Cell. Cardiol., 1991, 
23, 841-850. 
[157] Du, X. J.; Anderson, K. E.; Jacobsen, A.; Woodcock, E. A.; Dart, 
A. M. Suppression of ventricular arrhythmias during ischemia-
reperfusion by agents inhibiting Ins(1,4,5)P3 release. Circulation, 
1995, 91, 2712-2716. 
[158] Akhter, S. A.; Luttrell, L. M.; Rockman, H. A.; Iaccarino, G.; 
Lefkowitz, R. J.; Koch, W. J. Targeting the receptor-Gq interface to 
inhibit in vivo pressure overload myocardial hypertrophy. Science, 
1998, 280, 574-577. 
[159] Wakasaki, H.; Koya, D.; Schoen, F. J.; Jirousek, M. R.; Ways, D. 
K.; Hoit, B. D.; Walsh, R. A.; King, G. L. Targeted overexpression 
of protein kinase C beta2 isoform in myocardium causes cardiomy-
opathy. Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 9320-9325. 
[160] Sorriento, D.; Santulli, G.; Fusco, A.; Anastasio, A.; Trimarco, B.; 
Iaccarino, G. Intracardiac injection of AdGRK5-NT reduces left 
ventricular hypertrophy by inhibiting NF-kappaB-dependent hyper-
trophic gene expression. Hypertension, 2010, 56, 696-704. 
[161] Rios, E.; Brum, G. Involvement of dihydropyridine receptors in 
excitation-contraction coupling in skeletal muscle. Nature, 1987, 
325, 717-720. 
[162] Nelson, B. R.; Wu, F.; Liu, Y.; Anderson, D. M.; McAnally, J.; 
Lin, W.; Cannon, S. C.; Bassel-Duby, R.; Olson, E. N. Skeletal 
muscle-specific T-tubule protein STAC3 mediates voltage-induced 
Ca2+ release and contractility. Proc. Natl. Acad. Sci. U. S. A., 2013, 
110, 11881-11886. 
[163] Block, B. A.; Imagawa, T.; Campbell, K. P.; Franzini-Armstrong, 
C. Structural evidence for direct interaction between the molecular 
components of the transverse tubule/sarcoplasmic reticulum junc-
tion in skeletal muscle. J. Cell Biol., 1988, 107, 2587-2600. 
[164] Wagenknecht, T.; Grassucci, R.; Frank, J.; Saito, A.; Inui, M.; 
Fleischer, S. Three-dimensional architecture of the calcium chan-
nel/foot structure of sarcoplasmic reticulum. Nature, 1989, 338, 
167-170. 
[165] Brandt, N. R.; Caswell, A. H.; Wen, S. R.; Talvenheimo, J. A. 
Molecular interactions of the junctional foot protein and dihydro-
pyridine receptor in skeletal muscle triads. J. Membr. Biol., 1990, 
113, 237-251. 
[166] Takeshima, H.; Iino, M.; Takekura, H.; Nishi, M.; Kuno, J.; Mi-
nowa, O.; Takano, H.; Noda, T. Excitation-contraction uncoupling 
and muscular degeneration in mice lacking functional skeletal mus-
cle ryanodine-receptor gene. Nature, 1994, 369, 556-559. 
[167] Takekura, H.; Nishi, M.; Noda, T.; Takeshima, H.; Franzini-
Armstrong, C. Abnormal junctions between surface membrane and 
sarcoplasmic reticulum in skeletal muscle with a mutation targeted 
to the ryanodine receptor. Proc. Natl. Acad. Sci. U. S. A., 1995, 92, 
3381-3385. 
[168] Nakai, J.; Dirksen, R. T.; Nguyen, H. T.; Pessah, I. N.; Beam, K. 
G.; Allen, P. D. Enhanced dihydropyridine receptor channel activ-
ity in the presence of ryanodine receptor. Nature, 1996, 380, 72-75. 
[169] Andersson, D. C.; Meli, A. C.; Reiken, S.; Betzenhauser, M. J.; 
Umanskaya, A.; Shiomi, T.; D'Armiento, J.; Marks, A. R. Leaky 
ryanodine receptors in beta-sarcoglycan deficient mice: a potential 
common defect in muscular dystrophy. Skelet Muscle, 2012, 2, 9. 
[170] Bellinger, A. M.; Mongillo, M.; Marks, A. R. Stressed out: the 
skeletal muscle ryanodine receptor as a target of stress. J. Clin. In-
vest., 2008, 118, 445-453. 
[171] Betzenhauser, M. J.; Marks, A. R. Ryanodine receptor channelo-
pathies. Pflugers Arch., 2010, 460, 467-480. 
[172] Censier, K.; Urwyler, A.; Zorzato, F.; Treves, S. Intracellular cal-
cium homeostasis in human primary muscle cells from malignant 
hyperthermia-susceptible and normal individuals. Effect Of over-
expression of recombinant wild-type and Arg163Cys mutated rya-
nodine receptors. J. Clin. Invest., 1998, 101, 1233-1242. 
[173] Larach, M. G.; Brandom, B. W.; Allen, G. C.; Gronert, G. A.; 
Lehman, E. B. Malignant Hyperthermia Deaths Related to Inade-
quate Temperature Monitoring, 2007-2012: A Report from The 
North American Malignant Hyperthermia Registry of the Malig-
nant Hyperthermia Association of the United States. Anesth. An-
alg., 2014. 
[174] Nelson, T. E.; Bee, D. E. Temperature perturbation studies of sar-
coplasmic reticulum from malignant hyperthermia pig muscle. J. 
Clin. Invest., 1979, 64, 895-901. 
[175] Mickelson, J. R.; Gallant, E. M.; Litterer, L. A.; Johnson, K. M.; 
Rempel, W. E.; Louis, C. F. Abnormal sarcoplasmic reticulum rya-
nodine receptor in malignant hyperthermia. J. Biol. Chem., 1988, 
263, 9310-9315. 
[176] Fill, M.; Coronado, R.; Mickelson, J. R.; Vilven, J.; Ma, J. J.; 
Jacobson, B. A.; Louis, C. F. Abnormal ryanodine receptor chan-
nels in malignant hyperthermia. Biophys. J., 1990, 57, 471-475. 
[177] Magee, K. R.; Shy, G. M. A new congenital non-progressive my-
opathy. Brain, 1956, 79, 610-621. 
[178] Zhou, H.; Jungbluth, H.; Sewry, C. A.; Feng, L.; Bertini, E.; 
Bushby, K.; Straub, V.; Roper, H.; Rose, M. R.; Brockington, M.; 
Kinali, M.; Manzur, A.; Robb, S.; Appleton, R.; Messina, S.; 
D'Amico, A.; Quinlivan, R.; Swash, M.; Muller, C. R.; Brown, S.; 
Treves, S.; Muntoni, F. Molecular mechanisms and phenotypic 
variation in RYR1-related congenital myopathies. Brain, 2007, 
130, 2024-2036. 
[179] Avila, G.; Dirksen, R. T. Functional effects of central core disease 
mutations in the cytoplasmic region of the skeletal muscle ryano-
dine receptor. J. Gen. Physiol., 2001, 118, 277-290. 
[180] Bharucha-Goebel, D. X.; Santi, M.; Medne, L.; Zukosky, K.; Dast-
gir, J.; Shieh, P. B.; Winder, T.; Tennekoon, G.; Finkel, R. S.; 
Dowling, J. J.; Monnier, N.; Bonnemann, C. G. Severe congenital 
RYR1-associated myopathy: the expanding clinicopathologic and 
genetic spectrum. Neurology, 2013, 80, 1584-1589. 
[181] Zvaritch, E.; Kraeva, N.; Bombardier, E.; McCloy, R. A.; Depreux, 
F.; Holmyard, D.; Kraev, A.; Seidman, C. E.; Seidman, J. G.; Tu-
pling, A. R.; MacLennan, D. H. Ca2+ dysregulation in 
Ryr1(I4895T/wt) mice causes congenital myopathy with progres-
sive formation of minicores, cores, and nemaline rods. Proc. Natl. 
Acad. Sci. U. S. A., 2009, 106, 21813-21818. 
[182] Ferreiro, A.; Monnier, N.; Romero, N. B.; Leroy, J. P.; Bonne-
mann, C.; Haenggeli, C. A.; Straub, V.; Voss, W. D.; Nivoche, Y.; 
Jungbluth, H.; Lemainque, A.; Voit, T.; Lunardi, J.; Fardeau, M.; 
Guicheney, P. A recessive form of central core disease, transiently 
presenting as multi-minicore disease, is associated with a homozy-
gous mutation in the ryanodine receptor type 1 gene. Ann. Neurol., 
2002, 51, 750-759. 
[183] Bellinger, A. M.; Reiken, S.; Carlson, C.; Mongillo, M.; Liu, X.; 
Rothman, L.; Matecki, S.; Lacampagne, A.; Marks, A. R. Hyperni-
trosylated ryanodine receptor calcium release channels are leaky in 
dystrophic muscle. Nat. Med., 2009, 15, 325-330. 
[184] Santulli, G. Adrenal signaling in heart failure: something more than 
a distant ship's smoke on the horizon. Hypertension, 2014, 63, 215-
216. 
[185] Dalla Libera, L.; Ravara, B.; Gobbo, V.; Danieli Betto, D.; Germi-
nario, E.; Angelini, A.; Vescovo, G. Skeletal muscle myofibrillar 
protein oxidation in heart failure and the protective effect of Carve-
dilol. J. Mol. Cell. Cardiol., 2005, 38, 803-807. 
[186] Ward, C. W.; Reiken, S.; Marks, A. R.; Marty, I.; Vassort, G.; 
Lacampagne, A. Defects in ryanodine receptor calcium release in 
skeletal muscle from post-myocardial infarct rats. FASEB J., 2003, 
17, 1517-1519. 
[187] Bellinger, A. M.; Reiken, S.; Dura, M.; Murphy, P. W.; Deng, S. 
X.; Landry, D. W.; Nieman, D.; Lehnart, S. E.; Samaru, M.; La-
Campagne, A.; Marks, A. R. Remodeling of ryanodine receptor 
complex causes "leaky" channels: a molecular mechanism for de-
IP3Rs and RyRs in Human Pathophysiology Current Molecular Pharmacology, 2015, Vol. 8, No. 2    15 
creased exercise capacity. Proc. Natl. Acad. Sci. U. S. A., 2008, 
105, 2198-2202. 
[188] Umanskaya, A.; Santulli, G.; Xie, W.; Andersson, D. C.; Reiken, S. 
R.; Marks, A. R. Genetically enhancing mitochondrial antioxidant 
activity improves muscle function in aging. Proc. Natl. Acad. Sci. 
U. S. A., 2014, 111, 15250-15255. 
[189] Moschella, M. C.; Watras, J.; Jayaraman, T.; Marks, A. R. Inositol 
1,4,5-trisphosphate receptor in skeletal muscle: differential expres-
sion in myofibres. J. Muscle Res. Cell Motil., 1995, 16, 390-400. 
[190] Salanova, M.; Priori, G.; Barone, V.; Intravaia, E.; Flucher, B.; 
Ciruela, F.; McIlhinney, R. A.; Parys, J. B.; Mikoshiba, K.; Sorren-
tino, V. Homer proteins and InsP(3) receptors co-localise in the 
longitudinal sarcoplasmic reticulum of skeletal muscle fibres. Cell 
Calcium, 2002, 32, 193-200. 
[191] Casas, M.; Figueroa, R.; Jorquera, G.; Escobar, M.; Molgo, J.; 
Jaimovich, E. IP(3)-dependent, post-tetanic calcium transients in-
duced by electrostimulation of adult skeletal muscle fibers. J. Gen. 
Physiol., 2010, 136, 455-467. 
[192] Stiber, J. A.; Tabatabaei, N.; Hawkins, A. F.; Hawke, T.; Worley, 
P. F.; Williams, R. S.; Rosenberg, P. Homer modulates NFAT-
dependent signaling during muscle differentiation. Dev. Biol., 
2005, 287, 213-224. 
[193] Powell, J. A.; Carrasco, M. A.; Adams, D. S.; Drouet, B.; Rios, J.; 
Muller, M.; Estrada, M.; Jaimovich, E. IP(3) receptor function and 
localization in myotubes: an unexplored Ca(2+) signaling pathway 
in skeletal muscle. J. Cell Sci., 2001, 114, 3673-3683. 
[194] Blaauw, B.; Del Piccolo, P.; Rodriguez, L.; Hernandez Gonzalez, 
V. H.; Agatea, L.; Solagna, F.; Mammano, F.; Pozzan, T.; Schiaf-
fino, S. No evidence for inositol 1,4,5-trisphosphate-dependent 
Ca2+ release in isolated fibers of adult mouse skeletal muscle. J. 
Gen. Physiol., 2012, 140, 235-241. 
[195] Powell, J. A.; Molgo, J.; Adams, D. S.; Colasante, C.; Williams, 
A.; Bohlen, M.; Jaimovich, E. IP3 receptors and associated Ca2+ 
signals localize to satellite cells and to components of the neuro-
muscular junction in skeletal muscle. J. Neurosci., 2003, 23, 8185-
8192. 
[196] Lessard, C. B.; Lussier, M. P.; Cayouette, S.; Bourque, G.; Boulay, 
G. The overexpression of presenilin2 and Alzheimer's-disease-
linked presenilin2 variants influences TRPC6-enhanced Ca2+ entry 
into HEK293 cells. Cell. Signal., 2005, 17, 437-445. 
[197] Zatti, G.; Ghidoni, R.; Barbiero, L.; Binetti, G.; Pozzan, T.; Faso-
lato, C.; Pizzo, P. The presenilin 2 M239I mutation associated with 
familial Alzheimer's disease reduces Ca2+ release from intracellular 
stores. Neurobiol. Dis., 2004, 15, 269-278. 
[198] Schapira, A. H.; Olanow, C. W.; Greenamyre, J. T.; Bezard, E. 
Slowing of neurodegeneration in Parkinson's disease and 
Huntington's disease: future therapeutic perspectives. Lancet, 2014, 
384, 545-555. 
[199] Arduino, D. M.; Esteves, A. R.; Cardoso, S. M.; Oliveira, C. R. 
Endoplasmic reticulum and mitochondria interplay mediates apop-
totic cell death: relevance to Parkinson's disease. Neurochem. Int., 
2009, 55, 341-348. 
[200] Takei, K.; Mignery, G. A.; Mugnaini, E.; Sudhof, T. C.; De 
Camilli, P. Inositol 1,4,5-trisphosphate receptor causes formation 
of ER cisternal stacks in transfected fibroblasts and in cerebellar 
Purkinje cells. Neuron, 1994, 12, 327-342. 
[201] Miller, M. C. Commentary. Did Lou Gehrig have Lou Gehrig's 
disease? Harv. Ment. Health Lett., 2011, 27, 8. 
[202] Cleveland, D. W.; Rothstein, J. D. From Charcot to Lou Gehrig: 
deciphering selective motor neuron death in ALS. Nat. Rev. Neuro-
sci., 2001, 2, 806-819. 
[203] Shampo, M. A.; Kyle, R. A. Lou Gehrig--amyotrophic lateral scle-
rosis. Mayo Clin. Proc., 1993, 68, 929. 
[204] Carlesi, C.; CaldarazzoIenco, E.; Mancuso, M.; Siciliano, G. 
Amyotrophic Lateral Sclerosis: A Genetic Point Of View. Curr. 
Mol. Med., 2014. 
[205] Hanrieder, J.; Ewing, A. G. Spatial elucidation of spinal cord lipid- 
and metabolite- regulations in amyotrophic lateral sclerosis. Sci. 
Rep., 2014, 4, 5266. 
[206] Chin, E. R.; Chen, D.; Bobyk, K.; Mazala, D. A. Perturbations in 
Intracellular Ca2+ Handling in Skeletal Muscle in the G93A*SOD1 
Mouse Model of Amyotrophic Lateral Sclerosis. Am. J. Physiol. 
Cell Physiol., 2014, ajpcell 00237 02013. 
[207] Tanaka, H.; Shimazawa, M.; Kimura, M.; Takata, M.; Tsuruma, K.; 
Yamada, M.; Takahashi, H.; Hozumi, I.; Niwa, J.; Iguchi, Y.; Ni-
kawa, T.; Sobue, G.; Inuzuka, T.; Hara, H. The potential of 
GPNMB as novel neuroprotective factor in amyotrophic lateral 
sclerosis. Sci. Rep., 2012, 2, 573. 
[208] Turner, M. R.; Goldacre, R.; Ramagopalan, S.; Talbot, K.; Gol-
dacre, M. J. Autoimmune disease preceding amyotrophic lateral 
sclerosis: an epidemiologic study. Neurology, 2013, 81, 1222-1225. 
[209] Antel, J. P.; Richman, D. P.; Arnason, B. G. Immunogenetics and 
amyotrophic lateral sclerosis. UCLA Forum Med. Sci., 1976, 151-
171. 
[210] Pagani, M. R.; Reisin, R. C.; Uchitel, O. D. Calcium signaling 
pathways mediating synaptic potentiation triggered by amyotrophic 
lateral sclerosis IgG in motor nerve terminals. J. Neurosci., 2006, 
26, 2661-2672. 
[211] van Es, M. A.; Van Vught, P. W.; Blauw, H. M.; Franke, L.; Saris, 
C. G.; Andersen, P. M.; Van Den Bosch, L.; de Jong, S. W.; van 't 
Slot, R.; Birve, A.; Lemmens, R.; de Jong, V.; Baas, F.; Schelhaas, 
H. J.; Sleegers, K.; Van Broeckhoven, C.; Wokke, J. H.; Wijmenga, 
C.; Robberecht, W.; Veldink, J. H.; Ophoff, R. A.; van den Berg, L. 
H. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral 
sclerosis: a genome-wide association study. Lancet Neurol., 2007, 
6, 869-877. 
[212] Kihira, T.; Utunomiya, H.; Kondo, T. Expression of FKBP12 and 
ryanodine receptors (RyRs) in the spinal cord of MND patients. 
Amyotroph. Lateral Scler. Other Motor Neuron Disord., 2005, 6, 
94-99. 
[213] Rivera, V. M.; Breitbach, W. B.; Swanke, L. Letter: Dantrolene in 
amyotrophic lateral sclerosis. JAMA, 1975, 233, 863-864. 
[214] Chamberlain, B. K.; Volpe, P.; Fleischer, S. Inhibition of calcium-
induced calcium release from purified cardiac sarcoplasmic reticu-
lum vesicles. J. Biol. Chem., 1984, 259, 7547-7553. 
[215] Zhao, F.; Li, P.; Chen, S. R.; Louis, C. F.; Fruen, B. R. Dantrolene 
inhibition of ryanodine receptor Ca2+ release channels. Molecular 
mechanism and isoform selectivity. J. Biol. Chem., 2001, 276, 
13810-13816. 
[216] Oo, Y. W.; Gomez-Hurtado, N.; Walweel, K.; van Helden, D. F.; 
Imtiaz, M. S.; Knollmann, B. C.; Laver, D. R. Essential Role of 
Calmodulin in RyR Inhibition by Dantrolene. Mol. Pharmacol., 
2015, 88, 57-63. 
[217] Stutzmann, G. E.; Caccamo, A.; LaFerla, F. M.; Parker, I. Dysregu-
lated IP3 signaling in cortical neurons of knock-in mice expressing 
an Alzheimer's-linked mutation in presenilin1 results in exagger-
ated Ca2+ signals and altered membrane excitability. J. Neurosci., 
2004, 24, 508-513. 
[218] Veeranna; Kaji, T.; Boland, B.; Odrljin, T.; Mohan, P.; Basavara-
jappa, B. S.; Peterhoff, C.; Cataldo, A.; Rudnicki, A.; Amin, N.; Li, 
B. S.; Pant, H. C.; Hungund, B. L.; Arancio, O.; Nixon, R. A. Cal-
pain mediates calcium-induced activation of the erk1,2 MAPK 
pathway and cytoskeletal phosphorylation in neurons: relevance to 
Alzheimer's disease. Am. J. Pathol., 2004, 165, 795-805. 
[219] Demuro, A.; Parker, I. Cytotoxicity of intracellular abeta42 amy-
loid oligomers involves Ca2+ release from the endoplasmic reticu-
lum by stimulated production of inositol trisphosphate. J. Neuro-
sci., 2013, 33, 3824-3833. 
[220] Ito, E.; Oka, K.; Etcheberrigaray, R.; Nelson, T. J.; McPhie, D. L.; 
Tofel-Grehl, B.; Gibson, G. E.; Alkon, D. L. Internal Ca2+ mobiliza-
tion is altered in fibroblasts from patients with Alzheimer disease. 
Proc. Natl. Acad. Sci. U. S. A., 1994, 91, 534-538. 
[221] Cheung, K. H.; Shineman, D.; Muller, M.; Cardenas, C.; Mei, L.; 
Yang, J.; Tomita, T.; Iwatsubo, T.; Lee, V. M.; Foskett, J. K. 
Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin 
regulation of InsP3 receptor channel gating. Neuron, 2008, 58, 871-
883. 
[222] Shilling, D.; Muller, M.; Takano, H.; Mak, D. O.; Abel, T.; Coul-
ter, D. A.; Foskett, J. K. Suppression of InsP3 receptor-mediated 
Ca2+ signaling alleviates mutant presenilin-linked familial Alz-
heimer's disease pathogenesis. J. Neurosci., 2014, 34, 6910-6923. 
[223] Kelliher, M.; Fastbom, J.; Cowburn, R. F.; Bonkale, W.; Ohm, T. 
G.; Ravid, R.; Sorrentino, V.; O'Neill, C. Alterations in the ryano-
dine receptor calcium release channel correlate with Alzheimer's 
disease neurofibrillary and beta-amyloid pathologies. Neurosci-
ence, 1999, 92, 499-513. 
[224] Stutzmann, G. E.; Smith, I.; Caccamo, A.; Oddo, S.; Parker, I.; 
Laferla, F. Enhanced ryanodine-mediated calcium release in mutant 
PS1-expressing Alzheimer's mouse models. Ann. N. Y. Acad. Sci., 
2007, 1097, 265-277. 
16    Current Molecular Pharmacology, 2015, Vol. 8, No. 2 Santulli and Marks 
[225] Liu, J.; Supnet, C.; Sun, S.; Zhang, H.; Good, L.; Popugaeva, E.; 
Bezprozvanny, I. The role of ryanodine receptor type 3 in a mouse 
model of Alzheimer disease. Channels, 2014, 8. 
[226] Antonell, A.; Llado, A.; Altirriba, J.; Botta-Orfila, T.; Balasa, M.; 
Fernandez, M.; Ferrer, I.; Sanchez-Valle, R.; Molinuevo, J. L. A 
preliminary study of the whole-genome expression profile of spo-
radic and monogenic early-onset alzheimer's disease. Neurobiol. 
Aging, 2013, 34, 1772-1778. 
[227] Alberdi, E.; Wyssenbach, A.; Alberdi, M.; Sanchez-Gomez, M. V.; 
Cavaliere, F.; Rodriguez, J. J.; Verkhratsky, A.; Matute, C. Ca(2+) 
-dependent endoplasmic reticulum stress correlates with astroglio-
sis in oligomeric amyloid beta-treated astrocytes and in a model of 
Alzheimer's disease. Aging Cell, 2013, 12, 292-302. 
[228] Czeredys, M.; Gruszczynska-Biegala, J.; Schacht, T.; Methner, A.; 
Kuznicki, J. Expression of genes encoding the calcium signalosome 
in cellular and transgenic models of Huntington's disease. Front. 
Mol. Neurosci., 2013, 6, 42. 
[229] Sun, Y.; Savanenin, A.; Reddy, P. H.; Liu, Y. F. Polyglutamine-
expanded huntingtin promotes sensitization of N-methyl-D-
aspartate receptors via post-synaptic density 95. J. Biol. Chem., 
2001, 276, 24713-24718. 
[230] Tang, T. S.; Tu, H.; Chan, E. Y.; Maximov, A.; Wang, Z.; Welling-
ton, C. L.; Hayden, M. R.; Bezprozvanny, I. Huntingtin and hunt-
ingtin-associated protein 1 influence neuronal calcium signaling 
mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron, 
2003, 39, 227-239. 
[231] Kaltenbach, L. S.; Romero, E.; Becklin, R. R.; Chettier, R.; Bell, 
R.; Phansalkar, A.; Strand, A.; Torcassi, C.; Savage, J.; Hurlburt, 
A.; Cha, G. H.; Ukani, L.; Chepanoske, C. L.; Zhen, Y.; Sahas-
rabudhe, S.; Olson, J.; Kurschner, C.; Ellerby, L. M.; Peltier, J. M.; 
Botas, J.; Hughes, R. E. Huntingtin interacting proteins are genetic 
modifiers of neurodegeneration. PLoS Genet., 2007, 3, e82. 
[232] Hoge, C. W.; Castro, C. A. Treatment of generalized war-related 
health concerns: placing TBI and PTSD in context. JAMA, 2014, 
312, 1685-1686. 
[233] Harvey, B. H.; Naciti, C.; Brand, L.; Stein, D. J. Serotonin and 
stress: protective or malevolent actions in the biobehavioral re-
sponse to repeated trauma? Ann. N. Y. Acad. Sci., 2004, 1032, 267-
272. 
[234] Liu, H.; Han, F.; Shi, Y. Effect of calreticulin on Ca2+ /CaM 
kinaseIIalpha and endoplasmic reticulum stress in hippocampal in a 
rat model of post-traumatic stress disorder. Neurochem. Res., 2013, 
38, 1407-1414. 
[235] Jacobi, H.; Bauer, P.; Giunti, P.; Labrum, R.; Sweeney, M. G.; 
Charles, P.; Durr, A.; Marelli, C.; Globas, C.; Linnemann, C.; 
Schols, L.; Rakowicz, M.; Rola, R.; Zdzienicka, E.; Schmitz-
Hubsch, T.; Fancellu, R.; Mariotti, C.; Tomasello, C.; Baliko, L.; 
Melegh, B.; Filla, A.; Rinaldi, C.; van de Warrenburg, B. P.; Ver-
stappen, C. C.; Szymanski, S.; Berciano, J.; Infante, J.; Timmann, 
D.; Boesch, S.; Hering, S.; Depondt, C.; Pandolfo, M.; Kang, J. S.; 
Ratzka, S.; Schulz, J.; Tezenas du Montcel, S.; Klockgether, T. The 
natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year 
follow-up study. Neurology, 2011, 77, 1035-1041. 
[236] Matsumoto, M.; Nakagawa, T.; Inoue, T.; Nagata, E.; Tanaka, K.; 
Takano, H.; Minowa, O.; Kuno, J.; Sakakibara, S.; Yamada, M.; 
Yoneshima, H.; Miyawaki, A.; Fukuuchi, Y.; Furuichi, T.; Okano, 
H.; Mikoshiba, K.; Noda, T. Ataxia and epileptic seizures in mice 
lacking type 1 inositol 1,4,5-trisphosphate receptor. Nature, 1996, 
379, 168-171. 
[237] Liu, J.; Tang, T. S.; Tu, H.; Nelson, O.; Herndon, E.; Huynh, D. P.; 
Pulst, S. M.; Bezprozvanny, I. Deranged calcium signaling and 
neurodegeneration in spinocerebellar ataxia type 2. J. Neurosci., 
2009, 29, 9148-9162. 
[238] Chen, X.; Tang, T. S.; Tu, H.; Nelson, O.; Pook, M.; Hammer, R.; 
Nukina, N.; Bezprozvanny, I. Deranged calcium signaling and neu-
rodegeneration in spinocerebellar ataxia type 3. J. Neurosci., 2008, 
28, 12713-12724. 
[239] van de Leemput, J.; Chandran, J.; Knight, M. A.; Holtzclaw, L. A.; 
Scholz, S.; Cookson, M. R.; Houlden, H.; Gwinn-Hardy, K.; Fung, 
H. C.; Lin, X.; Hernandez, D.; Simon-Sanchez, J.; Wood, N. W.; 
Giunti, P.; Rafferty, I.; Hardy, J.; Storey, E.; Gardner, R. J.; 
Forrest, S. M.; Fisher, E. M.; Russell, J. T.; Cai, H.; Singleton, A. 
B. Deletion at ITPR1 underlies ataxia in mice and spinocerebellar 
ataxia 15 in humans. PLoS Genet., 2007, 3, e108. 
[240] Iwaki, A.; Kawano, Y.; Miura, S.; Shibata, H.; Matsuse, D.; Li, W.; 
Furuya, H.; Ohyagi, Y.; Taniwaki, T.; Kira, J.; Fukumaki, Y. Het-
erozygous deletion of ITPR1, but not SUMF1, in spinocerebellar 
ataxia type 16. J. Med. Genet., 2008, 45, 32-35. 
[241] Street, V. A.; Bosma, M. M.; Demas, V. P.; Regan, M. R.; Lin, D. 
D.; Robinson, L. C.; Agnew, W. S.; Tempel, B. L. The type 1 
inositol 1,4,5-trisphosphate receptor gene is altered in the opistho-
tonos mouse. J. Neurosci., 1997, 17, 635-645. 
[242] Ye, R.; Ni, M.; Wang, M.; Luo, S.; Zhu, G.; Chow, R. H.; Lee, A. 
S. Inositol 1,4,5-trisphosphate receptor 1 mutation perturbs glucose 
homeostasis and enhances susceptibility to diet-induced diabetes. J. 
Endocrinol., 2011, 210, 209-217. 
[243] Tubbs, E.; Theurey, P.; Vial, G.; Bendridi, N.; Bravard, A.; Chau-
vin, M. A.; Ji-Cao, J.; Zoulim, F.; Bartosch, B.; Ovize, M.; Vidal, 
H.; Rieusset, J. Mitochondria-associated endoplasmic reticulum 
membrane (MAM) integrity is required for insulin signaling and is 
implicated in hepatic insulin resistance. Diabetes, 2014, 63, 3279-
3294. 
[244] Tsai, S. H.; Chang, E. Y.; Chang, Y. C.; Hee, S. W.; Tsai, Y. C.; 
Chang, T. J.; Chuang, L. M. Knockdown of RyR3 enhances adi-
ponectin expression through an atf3-dependent pathway. Endocri-
nology, 2013, 154, 1117-1129. 
[245] Santulli, G. Effects of low-carbohydrate and low-fat diets. Ann. 
Intern. Med., 2015, 162, 392. 
[246] Waluk, D. P.; Vielfort, K.; Derakhshan, S.; Aro, H.; Hunt, M. C. N-
Acyl taurines trigger insulin secretion by increasing calcium flux in 
pancreatic beta-cells. Biochem. Biophys. Res. Commun., 2013, 430, 
54-59. 
[247] De Marchi, U.; Thevenet, J.; Hermant, A.; Dioum, E.; Wiederkehr, 
A. Calcium co-regulates oxidative metabolism and ATP synthase-
dependent respiration in pancreatic beta cells. J. Biol. Chem., 2014, 
289, 9182-9194. 
[248] DeFronzo, R. A. Banting Lecture. From the triumvirate to the omi-
nous octet: a new paradigm for the treatment of type 2 diabetes 
mellitus. Diabetes, 2009, 58, 773-795. 
[249] Santulli, G.; Lombardi, A.; Sorriento, D.; Anastasio, A.; Del Gi-
udice, C.; Formisano, P.; Beguinot, F.; Trimarco, B.; Miele, C.; 
Iaccarino, G. Age-related impairment in insulin release: the essen-
tial role of beta(2)-adrenergic receptor. Diabetes, 2012, 61, 692-
701. 
[250] Lee, B.; Laychock, S. G. Inositol 1,4,5-trisphosphate receptor iso-
form expression in mouse pancreatic islets: effects of carbachol. 
Biochem. Pharmacol., 2001, 61, 327-336. 
[251] Madec, A. M.; Cassel, R.; Dubois, S.; Ducreux, S.; Vial, G.; Chau-
vin, M. A.; Mesnier, A.; Chikh, K.; Bosco, D.; Rieusset, J.; Van 
Coppenolle, F.; Thivolet, C. Losartan, an angiotensin II type 1 re-
ceptor blocker, protects human islets from glucotoxicity through 
the phospholipase C pathway. FASEB J., 2013, 27, 5122-5130. 
[252] Johnson, J. D.; Kuang, S.; Misler, S.; Polonsky, K. S. Ryanodine 
receptors in human pancreatic beta cells: localization and effects on 
insulin secretion. FASEB J., 2004, 18, 878-880. 
[253] Dror, V.; Kalynyak, T. B.; Bychkivska, Y.; Frey, M. H.; Tee, M.; 
Jeffrey, K. D.; Nguyen, V.; Luciani, D. S.; Johnson, J. D. Glucose 
and endoplasmic reticulum calcium channels regulate HIF-1beta 
via presenilin in pancreatic beta-cells. J. Biol. Chem., 2008, 283, 
9909-9916. 
[254] Dadi, P. K.; Vierra, N. C.; Ustione, A.; Piston, D. W.; Colbran, R. 
J.; Jacobson, D. A. Inhibition of pancreatic beta-cell Ca2+ 
/calmodulin-dependent protein kinase II reduces glucose-stimulated 
calcium influx and insulin secretion, impairing glucose tolerance. J. 
Biol. Chem., 2014, 289, 12435-12445. 
[255] Futatsugi, A.; Nakamura, T.; Yamada, M. K.; Ebisui, E.; Naka-
mura, K.; Uchida, K.; Kitaguchi, T.; Takahashi-Iwanaga, H.; Noda, 
T.; Aruga, J.; Mikoshiba, K. IP3 receptor types 2 and 3 mediate 
exocrine secretion underlying energy metabolism. Science, 2005, 
309, 2232-2234. 
[256] Roach, J. C.; Deutsch, K.; Li, S.; Siegel, A. F.; Bekris, L. M.; Ein-
haus, D. C.; Sheridan, C. M.; Glusman, G.; Hood, L.; Lernmark, 
A.; Janer, M. Genetic mapping at 3-kilobase resolution reveals 
inositol 1,4,5-triphosphate receptor 3 as a risk factor for type 1 dia-
betes in Sweden. Am. J. Hum. Genet., 2006, 79, 614-627. 
[257] Qu, H. Q.; Marchand, L.; Szymborski, A.; Grabs, R.; Polychrona-
kos, C. The association between type 1 diabetes and the ITPR3 
gene polymorphism due to linkage disequilibrium with HLA class 
II. Genes Immun., 2008, 9, 264-266. 
[258] Srivastava, M.; Atwater, I.; Glasman, M.; Leighton, X.; Goping, 
G.; Caohuy, H.; Miller, G.; Pichel, J.; Westphal, H.; Mears, D.; Ro-
jas, E.; Pollard, H. B. Defects in inositol 1,4,5-trisphosphate recep-
IP3Rs and RyRs in Human Pathophysiology Current Molecular Pharmacology, 2015, Vol. 8, No. 2    17 
tor expression, Ca(2+) signaling, and insulin secretion in the 
anx7(+/-) knockout mouse. Proc. Natl. Acad. Sci. U. S. A., 1999, 
96, 13783-13788. 
[259] Dyachok, O.; Tufveson, G.; Gylfe, E. Ca2+ -induced Ca2+ release by 
activation of inositol 1,4,5-trisphosphate receptors in primary pan-
creatic beta-cells. Cell Calcium, 2004, 36, 1-9. 
[260] Lemmens, R.; Larsson, O.; Berggren, P. O.; Islam, M. S. Ca2+ -
induced Ca2+ release from the endoplasmic reticulum amplifies the 
Ca2+ signal mediated by activation of voltage-gated L-type Ca2+ 
channels in pancreatic beta-cells. J. Biol. Chem., 2001, 276, 9971-
9977. 
[261] Mitchell, K. J.; Lai, F. A.; Rutter, G. A. Ryanodine receptor type I 
and nicotinic acid adenine dinucleotide phosphate receptors medi-
ate Ca2+ release from insulin-containing vesicles in living pancre-
atic beta-cells (MIN6). J. Biol. Chem., 2003, 278, 11057-11064. 
[262] Noguchi, N.; Yoshikawa, T.; Ikeda, T.; Takahashi, I.; Shervani, N. 
J.; Uruno, A.; Yamauchi, A.; Nata, K.; Takasawa, S.; Okamoto, H.; 
Sugawara, A. FKBP12.6 disruption impairs glucose-induced insu-
lin secretion. Biochem. Biophys. Res. Commun., 2008, 371, 735-
740. 
[263] Sardu, C.; Marfella, R.; Santulli, G. Impact of diabetes mellitus on 
the clinical response to cardiac resynchronization therapy in elderly 
people. J. Cardiovasc. Transl. Res., 2014, 7, 362-368. 
[264] Marks, A. R. Calcium cycling proteins and heart failure: mecha-
nisms and therapeutics. J. Clin. Invest., 2013, 123, 46-52. 
[265] Applegate, T. L.; Karjalainen, A.; Bygrave, F. L. Rapid Ca2+ influx 
induced by the action of dibutylhydroquinone and glucagon in the 
perfused rat liver. Biochem. J., 1997, 323 (Pt 2), 463-467. 
[266] Ozcan, L.; Wong, C. C.; Li, G.; Xu, T.; Pajvani, U.; Park, S. K.; 
Wronska, A.; Chen, B. X.; Marks, A. R.; Fukamizu, A.; Backs, J.; 
Singer, H. A.; Yates, J. R., 3rd; Accili, D.; Tabas, I. Calcium sig-
naling through CaMKII regulates hepatic glucose production in 
fasting and obesity. Cell Metab., 2012, 15, 739-751. 
[267] Wang, Y.; Li, G.; Goode, J.; Paz, J. C.; Ouyang, K.; Screaton, R.; 
Fischer, W. H.; Chen, J.; Tabas, I.; Montminy, M. Inositol-1,4,5-
trisphosphate receptor regulates hepatic gluconeogenesis in fasting 
and diabetes. Nature, 2012, 485, 128-132. 
[268] Contreras-Ferrat, A.; Llanos, P.; Vasquez, C.; Espinosa, A.; Oso-
rio-Fuentealba, C.; Arias-Calderon, M.; Lavandero, S.; Klip, A.; 
Hidalgo, C.; Jaimovich, E. Insulin elicits a ROS-activated and an 
IP3-dependent Ca2+ release, which both impinge on GLUT4 trans-
location. J. Cell Sci., 2014, 127, 1911-1923. 
[269] Weinstein, S. P.; O'Boyle, E.; Haber, R. S. Thyroid hormone in-
creases basal and insulin-stimulated glucose transport in skeletal 
muscle. The role of GLUT4 glucose transporter expression. Diabe-
tes, 1994, 43, 1185-1189. 
[270] Rogers, M. A.; Evans, W. J. Changes in skeletal muscle with aging: 
effects of exercise training. Exerc. Sport Sci. Rev., 1993, 21, 65-
102. 
[271] Gonzalez, E.; Messi, M. L.; Zheng, Z.; Delbono, O. Insulin-like 
growth factor-1 prevents age-related decrease in specific force and 
intracellular Ca2+ in single intact muscle fibres from transgenic 
mice. J. Physiol., 2003, 552, 833-844. 
[272] Herndon, L. A.; Schmeissner, P. J.; Dudaronek, J. M.; Brown, P. 
A.; Listner, K. M.; Sakano, Y.; Paupard, M. C.; Hall, D. H.; Dris-
coll, M. Stochastic and genetic factors influence tissue-specific de-
cline in ageing C. elegans. Nature, 2002, 419, 808-814. 
[273] Iwasa, H.; Yu, S.; Xue, J.; Driscoll, M. Novel EGF pathway regula-
tors modulate C. elegans healthspan and lifespan via EGF receptor, 
PLC-gamma, and IP3R activation. Aging Cell, 2010, 9, 490-505. 
[274] Thomas, M. M.; Vigna, C.; Betik, A. C.; Tupling, A. R.; Hepple, R. 
T. Initiating treadmill training in late middle age offers modest ad-
aptations in Ca2+ handling but enhances oxidative damage in senes-
cent rat skeletal muscle. Am. J. Physiol. Regul. Integr. Comp. 
Physiol., 2010, 298, R1269-1278. 
[275] Klitgaard, H.; Ausoni, S.; Damiani, E. Sarcoplasmic reticulum of 
human skeletal muscle: age-related changes and effect of training. 
Acta Physiol., 1989, 137, 23-31. 
[276] Russ, D. W.; Grandy, J. S.; Toma, K.; Ward, C. W. Ageing, but not 
yet senescent, rats exhibit reduced muscle quality and sarcoplasmic 
reticulum function. Acta Physiol., 2011, 201, 391-403. 
[277] Xiao, R. P.; Spurgeon, H. A.; O'Connor, F.; Lakatta, E. G. Age-
associated changes in beta-adrenergic modulation on rat cardiac 
excitation-contraction coupling. J. Clin. Invest., 1994, 94, 2051-
2059. 
[278] Lim, C. C.; Apstein, C. S.; Colucci, W. S.; Liao, R. Impaired cell 
shortening and relengthening with increased pacing frequency are 
intrinsic to the senescent mouse cardiomyocyte. J. Mol. Cell. Car-
diol., 2000, 32, 2075-2082. 
[279] Isenberg, G.; Borschke, B.; Rueckschloss, U. Ca2+ transients of 
cardiomyocytes from senescent mice peak late and decay slowly. 
Cell Calcium, 2003, 34, 271-280. 
[280] Santulli, G.; Totary-Jain, H. Tailoring mTOR-based therapy: mo-




Received: December 24, 2014 Revised: February 2, 2015 Accepted: April 20, 2015 
